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Drug delivery aims to optimize the systemic distribution of administered drugs to reach their 
target tissue in an effective and specific manner. This approach is arising also in the field of cancer 
therapy, since traditional small molecule chemotherapeutics can cause severe side effects and 
more sophisticated biomolecular therapeutics cannot always reach the target cells on their own. 
For these purposes, therapeutics can be packed into carriers that improve their pharmacokinetics 
by providing a suitable, protected environment for the cargo to travel in the body, armed with 
targeting molecules that guide them to the site of interest. Synthetic drug carriers include 
liposomes, porous silica and different polymer particles that can be modified to contain necessary 
surface structures for targeted delivery and improved biocompatibility. While they have shown 
much promise in research settings, their success in cancer treatment has been limited to only a 
handful of commercially available formulations, some of which have presented liver toxicity as a 
result of continuous administration. Additionally, targeting cancer cells is difficult because cancer 
is a very individual disease, and heterogeneity exists even within tumors, so finding any universal 
cancer-specific markers to target is extremely challenging. 
Nature has adopted a similar approach for delivering molecules containing 
biologically functional cargo from cell to cell. These naturally occurring carriers are called 
extracellular vesicles (EVs), in contrast to intracellular vesicles that mediate cargo trafficking inside 
of the cells. EVs are 50 – 1000 nm in diameter, consisting of a lipid bilayer with embedded 
membrane proteins that encloses water-soluble biological cargo within. Their exact composition 
and cargo vary from cell to cell and depending on the condition of the cells that produce them. 
Additionally, cells have multiple pathways for EV secretion and production. For these reasons EVs 
comprise a very heterogeneous population of vesicles in composition and they also have multiple 
biological functions that have not been completely clarified yet. EVs have been found in practically 
all body fluids and organisms that have been studied, taking part in the normal and pathological 
functions of the organism. For example, procoagulant EVs are found in blood and saliva that 
participate in hemostasis, while EVs secreted by cancer cells promote the survival, growth and 
metastasis of the tumor. They are able to affect cells via membrane interactions and by delivering 
functional cargo into their recipient cells. It has been shown that EVs are even able to target cells 
selectively by binding to specific cellular receptors, enabling targeted cargo delivery.  
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Given their natural cargo delivery properties, EVs present remarkable potential for 
drug delivery applications. As cancer cells also use EVs to communicate with each other, their EVs 
reflect the same heterogeneity that exists within the cells themselves, and may provide useful 
insights for cancer-targeted drug delivery. However, the internalization mechanisms of drug-
carrying EVs and especially the fate of the drugs they carry is not well understood. In this thesis, 
the use of EVs was assessed for the delivery of chemotherapeutic drug paclitaxel and an oncolytic 
adenovirus that represent small molecular and biological chemotherapeutics, with cancer cell-
derived EVs as the model carrier. The studies presented here focus on the preparation, 
characterization, intracellular tracking and effectiveness of these EVs for cancer therapy. The 
obtained results provide novel methods and knowledge for the future development of EV-based 
therapeutics for the treatment of cancer. First, EVs were loaded with paclitaxel by incubation, 
which enhanced the cytotoxic effect of the drug, changing its internalization from passive diffusion 
to endocytosis. A novel approach using fluorescence lifetime microscopy was introduced for 
tracking the release of paclitaxel from the EVs inside of the cells, identifying distinct patterns of 
subcellular drug release in individual cells and its intracellular kinetics. This method was able to 
show details about the drug release mediated by EVs that could not be observed with 
conventional fluorescence microscopy. Additionally, the relationship between EVs and 
adenoviruses was explored, revealing a previously undocumented pathway of spreading 
adenoviral infection via EVs. This EV-mediated infective delivery of the viral genome occurred 
separately from the classical pathway of adenoviral life cycle, and produced infective particles 
resembling EVs more than virions. EVs can in theory enhance the pharmacokinetics of oncolytic 
viruses by hiding them from the immune system and providing them alternative pathways for cell 
targeting and internalization, however it was found that infective EVs do react with adenovirus 
neutralizing antibodies. Taken together, these results suggest that EVs can act as versatile carriers 
of therapeutic cargo for cancer treatment, ranging from small molecule chemotherapeutics to 
oncolytic viruses, though they require further development. New methods are reported constantly 
for preparing and studying therapeutic EVs with new, innovative approaches that will help in the 
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1.1 Extracellular vesicles 
Extracellular vesicles (EVs) are submicron sized membrane particles that all cells secrete into their 
surroundings. While their physiological relevance is not completely understood yet, they have 
been shown to mediate cell-to-cell communication, between both short and long distances within 
an organism. Given their large size compared to other intercellular messengers, such as hormones, 
the structure and composition of EVs is very complex (Figure 1). They are also affected by the type 
of the EV secreting cell and its status, which are then both reflected on the EVs and their function. 
Furthermore, several cellular pathways for EV generation have been identified, adding even more 
to their heterogeneity in the form of EV subtypes. Taken together, these qualities make EVs an 
extremely versatile and flexible intercellular communication system. While different cells of all 
organisms have been shown to secrete EVs, here we will focus on the EVs of mammalian cells, as 
they are the most relevant regarding therapeutic or drug delivery applications, with an emphasis 
on the role of EVs in the progression of cancer. 
Figure 1: Structure of EVs. A: Schematic representation of EV structure. EVs are composed of a membrane 
that contains lipids (blue) and membrane proteins (red) that encloses intraluminal contents, including 
soluble proteins, nucleic acids (green) and metabolites (yellow). B: Cryo-electron micrograph of EVs. A 
picture of two PC-3 EVs from study (III) that was acquired using cryo-transmission electron microscopy. 
While the sizes of the EVs are similar, the EV on the left contains three membranes, while the one on the 
right only has one membrane. 
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1.1.1 Biogenesis of extracellular vesicles 
Several biogenesis pathways have been identified for EVs, which is one way to classify EV subtypes 
(van Niel, D'Angelo & Raposo, 2018). The coexistence of parallel pathways for EV biogenesis is one 
of the major factors contributing to the observed heterogeneity in the isolated EV populations. 
Three of the most commonly described subtypes are i) exosomes, ii) microvesicles and iii) 
apoptotic bodies, all with distinct mechanisms of generation that may vary in their details 
depending on the cell type. Apoptotic bodies are a type of EVs with a widely varying diameter 
from approximately 50 nm up to several micrometers that bud from cells undergoing programmed 
cell death and thus differ fundamentally from the other EV subtypes. Exosomes are formed in the 
endosomal network of the cell by inward budding of late endosomes. This creates intraluminal 
vesicles inside the endosome, turning it into a multivesicular body that can eventually fuse with 
the plasma membrane releasing the intraluminal vesicles, now termed exosomes. Microvesicles, 
on the other hand, are formed at the plasma membrane by a similar budding process, with the 
generated vesicles getting released straight into the extracellular space. The budding of both 
exosomes and microvesicles both require the accumulation of specific lipid species and proteins 
associated with the budding process and cargo sorting at the vesicle budding site (van Niel, 
D'Angelo & Raposo, 2018).  
Some of the most important proteins involved in the EV formation and cargo loading 
are those of the endosomal sorting complex required for transport (ESCRT), which mediate the 
clustering of lipid and protein cargo and structural elements and the following vesicle budding 
event as well (Colombo et al., 2013). Four ESCRT complexes have been identified, which form the 
machinery for budding and cargo sorting of intraluminal vesicles forming in multivesicular bodies 
(Christ et al., 2017): ESCRT-0 binds monoubiquitinated membrane proteins and 
phosphatidylinositol-3-phosphate at the budding site, causing their accumulation by forming 
multiprotein scaffolds with clathrin. ESCRT-I then binds ESCRT-0, in turn recruiting ESCRT-III with 
either ESCRT-II or Alix. ESCRT-III then mediates scission of the forming vesicle with VPS4(Adell et 
al., 2014). Exosomes can also be formed through ESCRT-independent pathways, involving a 
protein complex formed by syndecan, syntenin and Alix, the accumulation of ceramide or proteins 
of the tetraspanin family, especially CD63 (Trajkovic et al., 2008, Edgar, Eden & Futter, 2014). 
These pathways induce membrane curvature and clustering of cargo at the budding sites in 
multivesicular bodies, followed by detaching of the vesicle from the membrane. Several post-
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translational modifications have been found enriched in EV-associated cargo proteins, including 
ubiquitination, SUMOylation, phosphorylation, specific glycosylation patterns and more, indicating 
that cargo sorting into EVs is at least partly regulated by these modifications, which may be bound 
by ESCRT proteins, tetraspanins or ceramide during vesicle formation (Anand et al., 2019). While 
there are similarities between the budding process of microvesicles and exosomes, the budding of 
microvesicles is dependent on the asymmetric accumulation of lipids such as phosphatidylserine 
(PS) and cytoskeleton reorganization at the budding site, because for membrane budding to occur 
at the plasma membrane, cytoskeleton-plasma membrane connections must be flexible enough to 
allow localized membrane curvature. These events are mediated by Ca2+-dependent lipid 
translocases, calpain or protein kinase C (Gonzalez et al., 2009, Stratton et al., 2015, Taylor, Jaiswal 
& Bebawy, 2017), and they are involved in the formation of the initial curvature of the budding 
membrane (Piccin, Murphy & Smith, 2007, Sidhu et al., 2004). Proteins of the ESCRT complex, such 
as TSG101 are recruited to the plasma membrane from the endosomes to mediate the budding 
and cargo sorting events of microvesicles (Nabhan et al., 2012). The final scission is usually 
executed by the contraction of actin and myosin, induced by GTP-binding proteins such as ADP 
ribosylation factors 6 and 1 (ARF6 and ARF1) (Muralidharan-Chari et al., 2009), ESCRT-III-
VPS4(Nabhan et al., 2012) or rho-associated, coiled coil containing protein kinases (ROCK) (Li et al., 
2012). 
 
1.1.2 Composition of extracellular vesicles  
The biogenesis of EVs involves the accumulation of lipids such as PS and ceramide to the budding 
site along with proteins of the ESCRT machinery or alternative proteins, which can selectively 
transport intended cargo molecules into the forming vesicles and then remain part of the EV 
structure when it detaches. Consequently, while EVs contain virtually all of the major types of 
biomolecules including lipids, proteins, nucleic acids and metabolites, the amount of these 
molecules in EVs may differ significantly compared to the cells they are derived from. Regarding 
the lipids that form the membrane structure, certain species are concentrated in EVs most likely to 
support the strong membrane curvature that is required due to their small size (Figure 2). Lipids 





Figure 2: Schematic representation of lipid shapes and their effect on membrane curvature. A: 
Classification of lipids according to their approximate geometrical shape with examples of each group. The 
size of the lipid head group compared to their tail determines their overall shape, with cylindrical lipids 
having equal sized head and tail, while in conical lipids the differences in group size cause an irregular 
overall shape. B: The effect of lipid composition on membrane curvature. A relatively small membrane 
structure (left), such as those found in EVs, has stronger membrane curvature, leaving less room for 
cylindrical lipids. A larger membrane structure (right), such as those found in cells, requires more cylindrical 
lipids to reduce membrane curvature. 
 
either positive or negative curvature due to the relative size difference between their head and 
tail groups, which gives them a conical shape, while cylindrical lipids such as phosphatidylcholine 
(PC) have equal sized head and tail (Janmey, Kinnunen, 2006). EVs have been found to contain 
more conically shaped lipids and less cylindrical lipids, when compared to larger membrane 
structures such as cellular organelles (Llorente et al., 2013, Haraszti et al., 2016). EVs are especially 
enriched in cholesterol, which provides also membrane rigidity, while the amount of 
phospholipids is diminished as a result (Llorente et al., 2013, Brzozowski et al., 2018). Also, the 
lipids in EVs appear to be more saturated. While tail length and saturation level of phospholipids 
also affect their shape, the head group appears to be the most important determining factor for 
enrichment in EVs, as head group distribution in EVs contains more variation compared to the 
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cells’ lipid profile than tail length and saturation. The phospholipid composition found in EVs 
includes less phosphatidylcholine and more PS, which is required in the initial phases of 
microvesicle budding. Other, less abundant phospholipids including PI and phosphatidylglycerol 
are more enriched in cells than EVs and the amount of glycerolipids is approximately the same in 
both cells and EVs. While sphingolipids are also enriched in EVs compared to cells, sphingomyelin 
and its derivatives have a cylindrical structure (Janmey, Kinnunen, 2006, Goñi, Alonso, 2006). 
Therefore, the role of sphingomyelins cannot be explained with supporting membrane curvature, 
i.e. they could be replaced by much more prevalent PC. Hence sphingomyelins must have a 
specific, functional role. Indeed, sphingolipids are considered to be the most complex lipids of all, 
because they are also glycosylated and they have been found to be involved in cell recognition and 
signaling (Hannun, Obeid, 2008). Sphingolipids can also form lipid raft-like structures on EVs that 
act as scaffolding sites for certain membrane proteins, given that lipid rafts provide another 
alternate mechanism for EV cargo sorting (Gassart et al., 2015). As with cellular membranes, the 
lipids are asymmetrically distributed in the EV membrane into the outer and inner leaflets 
(Llorente et al., 2013). While the lipid distribution has not been extensively studied, EVs display PS 
on their outer leaflet, which is considered a marker for apoptotic cells and acts as an “eat me” 
signal to phagocytes, or in the case of activated platelets, exposed PS promotes coagulation (Frey, 
Gaipl, 2011, Segawa, Nagata, 2015).  
 Proteomic meta-analyses indicate that most common cellular functions of EV-
associated proteins are related to signaling, transport events and cell motion (György et al., 2011, 
Choi et al., 2013). Additionally, the exact proteome of EVs varies heavily depending on the 
secreting cell, while their lipid composition appears to be relatively unchanged across different cell 
types (Haraszti et al., 2016, Brzozowski et al., 2018, Choi et al., 2013). The most commonly found 
EV-enriched proteins include tetraspanins such as CD9, CD63 and CD81, integrins, heat shock 
proteins, Alix, TSG101 and others that are associated with EV biogenesis or cargo sorting. These 
proteins are, therefore, commonly used as markers for EVs in research (Colombo, Raposo & Théry, 
2014). The EV-associated proteins have also been found to contain specific glycosylation patterns 
that vary between cell types and may act as protein sorting signals during EV biogenesis or in 
target recognition after secretion (Batista et al., 2011, Saraswat et al., 2014, Costa, 2017). More 
specifically, EVs from different cell types were all found to be enriched in polylactoseamine, α2-6 
linked sialic acid, high mannose and complex type glycans, while blood group antigens A and B 
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were not found in EVs. Because proteins have been shown to be able to retain their activities on 
EVs, they can together form functional units, with the EVs serving as scaffolds bringing them 
together. For example, cancer cells have been shown to secrete EVs that modify distant sites to 
develop so called metastatic niches, where circulating cancer cells can attach and grow metastases 
(Hood, Roman & Wickline, 2011, Hoshino et al., 2015). This can be accomplished via combining 
target recognition with appropriate cargo delivery, signaling via cell membrane receptors and even 
enzymatic activities that EVs may carry, such as matrix metalloproteases and other enzymes that 
cleave extracellular matrix in the target region to ease cancer cell attachment and growth (Nawaz 
et al., 2018).  
 Arguably, the most interesting cargo type identified in EVs so far is the nucleic acids. 
This interest is due to the observation that the nucleic acid content of EVs is able to affect the 
gene expression of the recipient cell as a type of horizontal gene transfer (Ratajczak et al., 2006, 
Waldenström et al., 2012, Cai et al., 2013, Cai et al., 2014, Wei et al., 2017, Hinger et al., 2018), 
thus having long lasting, profound effects on its function. These nucleic acid species include DNA 
and different types of RNA, such as messenger RNA (mRNA), micro RNA (miRNA) and other small 
RNA species (Sork et al., 2018, Thakur et al., 2014, Lunavat et al., 2015). The nucleic acid cargo of 
EVs therefore holds high potential for both therapeutic and diagnostic applications, as gene 
expression in target cells could be manipulated with regulatory RNAs incorporated with the EVs, 
while EVs could also provide a snapshot to the genetic or transcriptomic profile of diseased cells. 
For instance, mesenchymal stem cell-derived EVs have been shown to possess regenerative 
properties in organ damage that are RNA-dependent (Cantaluppi et al., 2012, Zou et al., 2016). 
These EVs were able to induce a significant decrease of miR-125b and cell proliferation in recipient 
leukemia and breast cancer cells even in vivo in mice. Also non-modified mesenchymal stem cell-
derived EVs have been shown to possess RNA-dependent organ regeneration-promoting 
properties (Zou et al., 2016). Compared to the cells of origin, cancerous or normal cells, the RNA 
profiles of EVs are enriched in smaller RNA species (25 - 1000 nucleotides), most of which are 
ribosomal or transfer RNA fragments and other more obscure RNA species with gene regulating 
properties, while the amount of miRNA and other regulatory RNA is lower (Wei et al., 2017, Hinger 
et al., 2018, Sork et al., 2018, Temoche-Diaz et al., 2019). Heterogeneity regarding the RNA size 
profiles has also been reported within EVs. EV-subtypes separated with differential centrifugation, 
density gradient or filtration approaches have been used to show that there are EV-size 
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dependent differences in their RNA-profiles, though the RNA enrichment patterns differ between 
individual studies (Wei et al., 2017, Lunavat et al., 2015, Temoche-Diaz et al., 2019). It is not yet 
understood, how DNA is included into EVs besides apoptotic bodies, but it has been shown to be 
present and taken up by the cells, affecting their gene expression (Waldenström et al., 2012, Cai et 
al., 2013, Cai et al., 2014, Kalluri, LeBleu, 2016, Takahashi et al., 2017). EVs have also been 
suggested to be a disposal mechanism for damaged, harmful DNA (Takahashi et al., 2017). Most of 
the DNA cargo has been suggested to being associated on the outer surface of EVs (Shelke et al., 
2016, Németh et al., 2017, Lázaro-Ibáñez et al., 2019), which may hold true also regarding some of 
the RNA cargo. Therapeutic effect of EVs in renal injury has been reported being abolished by 
RNase treatment (Cantaluppi et al., 2012, Zou et al., 2016), while the miRNA cargo of EVs has been 
shown to be RNase resistant in other studies (Temoche-Diaz et al., 2019, Shurtleff et al., 2016), 
demonstrating that RNA localization may vary between EVs of different sources. Localization of 
nucleic acids on the outer surface indicates an endosomal pathway for their loading, since the 
plasma membrane pathway of EV biogenesis would entail the outer surface of forming EVs being 
in contact with the extracellular space, in contrast to the endosomal pathway of exosome 
biogenesis. RNA cargo in EVs appears to contain targeting zipcode sequences and hair pin 
structures that may guide them into EVs during cargo loading or provide structural stability during 
transport (Batagov, Kuznetsov & Kurochkin, 2011, Batagov, Kurochkin, 2013, Villarroya-Beltri et 
al., 2013, Bolukbasi et al., 2012). hnRNPA2B1 in cells has been identified as a key protein involved 
in miRNA loading into EVs, recognizing a GGAG motif that is enriched in miRNAs found in EVs 
(Villarroya-Beltri et al., 2013).  Another zipcode was identified as a 25 nucleotide sequence with a 
CTGCC core that is recognized by miR-1289, which was found to mediate loading RNA into EVs 
(Bolukbasi et al., 2012). Several other miRNA-binding proteins have been identified as part of a 
sorting mechanism for different miRNA species to EVs (Temoche-Diaz et al., 2019, Shurtleff et al., 
2016, Mukherjee et al., 2016, Lu et al., 2017), demonstrating how complex the process of RNA 
sorting into EVs, suggesting that it is a highly regulated process and therefore a significant part of 
cells’ functions. 
 EVs have also been shown to contain metabolite profiles that differ significantly from 
their originating cells (Palviainen et al., 2019, Puhka et al., 2017). As metabolomics focuses on the 
analysis of the smallest molecules found in organisms, their chemical variety is much larger 
compared to other characterization methods. However, any conclusions regarding the biological 
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origin and relevance of the individual identified species are difficult to draw. EVs also possess 
enzymatic activities that can directly process and produce metabolites, therefore affecting the 
metabolome of recipient cells and even the one contained within EVs (Iraci et al., 2017). 
Nevertheless, certain enriched metabolic pathways have been found associated to the metabolites 
of EVs, including the urea cycle, amino acid, nucleotide and protein biosynthesis pathways 
(Palviainen et al., 2019, Puhka et al., 2017). As with other biomolecular cargo in EVs, their 
metabolome is affected by the state and type of the secreting cell (Palviainen et al., 2019). 
Therefore, the metabolic profile of EVs could be useful as a diagnostic tool or for monitoring the 
state of cell cultures.  
 
1.1.3 Internalization of extracellular vesicles 
In order to mediate their functions to cells, EVs can interact with them directly by signaling via 
receptors on the cell surface, such as MHC-I/-II to T-cells, leading to T-cell activation (Tkach et al., 
2017), as presented in figure 3. Alternatively, EVs are internalized by the recipient cell, leading to 
their intraluminal cargo release into the cytoplasm. EVs have been shown to be able to use all of 
the cellular uptake mechanism for cell entry, including direct fusion with the plasma membrane, 
different forms of endocytosis, phagocytosis and macropinocytosis (Mulcahy, Pink & Carter, 2014, 
Murphy et al., 2019). Different cell types have been shown to prefer certain mechanisms. For 
example, phagocytes have been suggested to mainly phagocytose EVs (Feng et al., 2010), although 
also other pathways have been shown being used significantly (Popēna et al., 2018), while in most 
other cell types endocytosis appears to be the most common pathway (Tian et al., 2010, Tian et 
al., 2013, Svensson et al., 2013, Nanbo et al., 2013). Regardless of the pathway, internalization of 
EVs begins with an interaction between the vesicle and internalizing cell surfaces. Binding of the 
EVs to the cell’s surface will eventually lead to the internalization of EVs via some of the many 
alternative pathways, though passive internalization of EVs has been excluded as EVs do not enter 
cells that have been fixed or kept at +4 °C (Tian et al., 2010, Tian et al., 2013, Svensson et al., 2013, 
Verdera et al., 2017). Receptor-mediated endocytosis and phagocytosis are triggered processes for 
the internalization of specific molecules, involving the formation of cargo-enveloping structures 




Figure 3: EV Internalization pathways and mechanisms for interactions with cells. EVs can interact with cells 
directly by binding to receptors on the cell membrane or after internalization by direct membrane fusion or 
different types of endocytosis, leading to a cellular response (lightning bolt). After internalization, whole 
EVs enter the endosomal network, which can lead to degradation by lysosomes or delivering their cargo to 
other cellular organelles.  
 
passive membrane recycling occurs routinely in all cells, which would also lead to the non-specific 
internalization of any plasma membrane-bound EVs, although this process is slower than receptor-
mediated endocytosis or phagocytosis. Macropinocytosis is also a non-specific process that cells 
use via cell membrane ruffles to uptake extracellular fluid, which can contain EVs as well in 
addition to any EVs bound to the plasma membrane, and therefore lead to their internalization. 
However, EVs and EV-associated endothelial growth factor have been shown to also promote 
macropinocytosis, and thus their own internalization through this pathway (Verdera et al., 2017, 
Nakase et al., 2015). Actin controlled cellular protrusions called filopodia have also been identified 
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as sites, where EV internalization appears to be enriched (Heusermann et al., 2016). Some 
commonly occurring surface structures relevant to EV-cell interactions have been identified that 
could lead to the non-specific internalization of EVs. These include glycan moieties such as heparin 
sulphate proteoglycans on both the cell and EV surfaces, lipid rafts (Svensson et al., 2013), and PS 
on EVs, which are recognized by several different receptors.  
Following the endocytosis of intact EVs, they follow the endosomal network into 
their subcellular destination (Tian et al., 2010, Tian et al., 2013, Svensson et al., 2013, Nanbo et al., 
2013, Ma et al., 2016). Internalized EVs have been observed to traffic to the endoplasmic 
reticulum (Heusermann et al., 2016), multivesicular bodies (Svensson et al., 2013) and lysosomes 
(Tian et al., 2013), though the exact fate of the cargo in EVs after internalization has not yet been 
clarified in detail. However, it has been shown that the lipids and proteins of EVs separate at some 
point inside the recipient cells, leading to EV protein accumulation to lysosomes, while the lipids 
may be retained as a part of the endosomal network and recycled to different membrane 
structures (Tian et al., 2010). Additionally, it was shown that inhibition of endosomal acidification 
prevented also the spreading of fluorescent lipid marker from EVs to the late endosome 
membrane (Nanbo et al., 2013). These observations suggest fusion of the EV membrane with the 
membranes of endosomes after internalization, leading to the release of the EV intraluminal cargo 
into the cytoplasm. In the case of fusion with the plasma membrane, the intraluminal cargo would 
be immediately released into the cytoplasm with the EV membrane integrating with the plasma 
membrane. The exact functions of these cargo molecules of course depend on their composition 
and structure, assuming that they survive degradation once inside the cell.  
 
1.1.4 Functions of extracellular vesicles in cancer 
While EVs participate in normally occurring functions that promote the physiological homeostasis 
of the host organism, cancer cells have been shown to secrete EVs that promote the progression 
of the disease. These EVs affect cells in their immediate vicinity and in more distal sites, both 
normal cells and other cancer cells. Several studies have reported that EVs from aggressive, i.e. 
quickly growing and spreading, cancer cells are more potent in promoting the different kinds of 
cancer promoting behavior in recipients than non-aggressive cancer cells. For instance, more 
metastatic cancer cells have been shown to promote a similar aggressive phenotype in other 
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cancer cells via EV-mediated delivery of oncogenes, causing increased invasiveness (Schillaci et al., 
2017, Yokoi et al., 2017), drug resistance (Dorayappan et al., 2018) and proliferation (Ozawa et al., 
2018), though EVs from non-aggressive cancer cells can also have similar effects (Raimondo et al., 
2015, Bouvy et al., 2017). Manipulating the healthy cells of the tumor microenvironment with 
cancer cell EVs has also been demonstrated to promote the progression of the disease. For 
example, fibroblasts, endothelial cells and immune cells have been identified as important targets 
for these EVs, each with distinct roles in tumor development. EVs from Hodgins’s lymphoma cells 
have been shown to attract and alter the phenotype of fibroblasts in the tumor microenvironment 
towards cancer associated fibroblasts, via the activation of inflammatory signaling pathways 
(Dörsam et al., 2018). Cancer associated fibroblasts secrete tumor growth supporting growth 
factors and RNA also within EVs (Richards et al., 2017, Nabet et al., 2017), demonstrating a bi-
directional feedback loop that is at least partially mediated by EVs. As the tumor grows, it 
becomes hypoxic and requires improved blood flow to continue growing. For this purpose, EVs 
from cancer cells have been shown to promote angiogenesis in the immediate environment of the 
tumor by transferring different RNA species and proteins such as miR-23a (Hsu et al., 2017), VEGF 
(Feng et al., 2017) and Wnt4(Huang, Feng, 2017) to endothelial cells, inducing the formation of 
new blood vessels. Many studies have also provided evidence that cancer cell derived EVs 
contribute to the perceived immune evasion of tumors by affecting different types of immune 
cells. For example, prostate cancer cells have been found to secrete EVs that induce pro-
inflammatory adenosine production in dendritic cells, inhibiting T-cell function (Salimu et al., 2017) 
and EVs from glioblastoma and colorectal cancer cells can modulate monocyte differentiation and 
affect their cytokine secretion to a generally more tumor benefiting profile (Popēna et al., 2018, 
de Vrij et al., 2015). Additionally, EVs from prostate and colorectal cancer cells have been found to 
inhibit T-cell proliferation and modulate a more tumor growth promoting, regulatory T-cell 
phenotype via TGF-β1-mediated signaling (Yamada et al., 2016).  
As mentioned above, cancer cell derived EVs are also able to promote the formation 
of pre-metastatic niches, where future metastases will form. EVs secreted by metastatic cancer 
cells can migrate to future sites for metastases and alter the cells at their destination. As different 
types of cancer have been identified as having tropisms for metastasizing in specific tissues, it has 
been suggested that the EVs that they secrete share those tropisms, determined by the integrin 
signature of the EVs (Hoshino et al., 2015). Thus EVs of metastatic cancer cells could be crucial in 
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choosing the site of future metastasis by recognizing and modifying it before circulating cancer 
cells can attach. It has also been shown that EVs induce vascular leakiness (Hoshino et al., 2015, 
Schillaci et al., 2017, Hsu et al., 2017), which has been proposed as a possible precursor for the 
niche formation, allowing the EVs and cancer cells to diffuse into the parenchyma through the 
leaky blood vessels (Hoshino et al., 2015). At the niche site, EVs can induce pro-metastatic 
microenvironment formation as discussed above, including promotion of angiogenesis, 
recruitment of cancer associated fibroblasts and pro-metastatic neutrophils through epithelial 
TLR3 activation (Liu et al., 2016) and modifying the extracellular matrix with matrix 
metalloproteinases they carry (Yue et al., 2015). Regarding the migration of metastatic cancer cells 
themselves, in addition to promoting vascular leakiness, cancer cell-derived EVs have also been 
shown to be able to cause degradation of the blood-brain-barrier through miR-181c-mediated 
disruption of actin organization in brain endothelial cells, allowing metastasizing cancer cells to 
migrate through the barrier and into the brain (Tominaga et al., 2015). Cancer cells can also use 
EVs to promote a transition to a more mobile phenotype through endothelial-mesenchymal 
transition (Yue et al., 2015) or by inducing an amoeboid phenotype in the cells (Schillaci et al., 
2017), which help the cancer cells’ detachment from the tumor and their survival in circulation. 
Overall, cancer cell derived EVs target both other cancer cells and healthy cells, promoting tumor 
growth via many complex mechanisms that may be significant in the development of the disease. 
For this reason, it is believed that there is also a lot of potential in using EVs as biomarkers for 
diagnosing cancer, since EVs contain abnormal cancer-related biomolecules (Xu et al., 2018), and it 
has also been proposed that removal of cancer cell-derived EVs from the blood could be a 








1.2 Extracellular vesicles as carriers of therapeutic cargo for cancer 
treatment 
In the last decade the scientific research in the field of EVs has grown exponentially, highlighting 
the rising importance and potential of EVs as carriers for targeted drug delivery, as reflected by 
the increase of publications (Figure 4). The key motivation towards developing EVs for therapeutic 
applications is that EVs are naturally occurring, functioning delivery vectors in humans and animals 
carrying biologically relevant information from cell to cell. 
 
Figure 4: Bar graph showing the number of publications referring to the use of EVs in drug delivery. An 
advanced search was performed in the Web of Science (accessed 10.6.19) to find all articles from years 
2006 - 2018 in English with the terms (“extracellular vesicles” OR ectosomes OR exosomes OR 
microvesicles”) and “drug delivery”. No articles matching the search criteria were found published prior to 
2006.  
 
Replacing or supplementing the natural cargo of EVs with a desired therapeutic load should 
therefore result in the delivery of therapeutics to the intended destination of the EVs. While EVs 
possess innate cell-mediated cargo loading and targeting properties, a major challenge for their 
use is posed by their rapid clearance by the mononuclear phagocyte system. In the following 
sections, these properties and challenges related to the preparation of therapeutic EVs are 





















for drug delivery purposes with a focus on cancer treatment. Examples of different cargo loading 
and targeting strategies with study outcomes are given at the end of section 1.2.3, in Table 1. 
 
1.2.1 Targeting and clearance of extracellular vesicles 
Targeted delivery of pharmaceuticals and biological therapeutics can enhance their desired effect 
dramatically while at the same time reducing the unwanted side-effects. In order to have any 
effect at all, therapeutics must reach the tissues, where they are needed. Because of their small 
size, it has been postulated that EVs would be well suited for cancer therapeutic applications due 
to the leaky vasculature of tumors, which leads to the passive accumulation of nanoparticles of 
approximately 100 nm in diameter, known as the enhanced permeation and retention (EPR) effect 
(Nichols, Bae, 2014). However, the EPR theory has been questioned based on the lack of success in 
human trials relying on EPR-mediated drug delivery (Nichols, Bae, 2014, Danhier, 2016) and the 
same negative result has been demonstrated in the case of EVs as well (Smyth et al., 2015). 
Therefore, the focus of therapeutic EV research is directed towards the development of actively 
targeting EVs carrying chemotherapeutics. Controlling the EV surface structures has been shown 
to translate to controlling their destination and interactions with the immune system. For 
example, it has been shown that the integrin signature of EVs is important in determining their 
target in metastatic organotropism, with the presence of integrins ITGα6, ITGβ4 and ITGβ1 
correlating with lung-tropism, while ITGβ5 led to liver-tropism in EVs from different metastatic 
cancer cells (Hoshino et al., 2015). Also, other targeting proteins on EVs have been identified, such 
as tetraspanins that are enriched in EVs (Rana et al., 2012). In theory, any protein on EVs that 
recognizes a specific surface structure on the target cells could be used as a targeting moiety. 
Therefore, targeting of EVs could be accomplished by choosing appropriate cell lines expressing 
the desired targeting components (Sancho-Albero et al., 2019). Modifying the parent cells 
producing EVs has been performed in several studies to include targeting moieties to the EVs, with 
small peptides, membrane proteins and antibody fragments being the most prominent 
(Gudbergsson et al., 2019). Targeting peptides for example include a fragment of the rabies virus 
glycoprotein, which binds specifically to acetylcholine receptors, which are enriched in nervous 
and muscle cells (Alvarez-Erviti et al., 2011), the transmembrane domain of platelet-derived 
growth factor receptor targeting epidermal growth factor receptor on breast cancer cells (Ohno et 
al., 2013) and αv integrin specific peptide iRGD for breast cancer targeting (Tian et al., 2014). 
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Addition of targeting moieties to EVs via GPI-anchoring is another viable alternative, as it does not 
interfere with the functionality of existing proteins, as demonstrated by engineering of EVs with 
nanobodies targeting EGFR (Kooijmans et al., 2016a). Modifications have also been applied to EVs 
in post-isolation to include targeting moieties onto the EV surface, such as lipid-linked hyaluronic 
acid that binds to CD44 that is enriched in cancer cells (Liu et al., 2019) or peptides that bind EV-
associated membrane proteins and can be used to crosslink cargo and targeting moieties to EVs 
(Gao et al., 2018). It is difficult to evaluate, whether there are any significant advantages gained 
from choosing either endogenous or exogenous targeting methods. As EVs from most cells are 
very heterogeneous in nature, any EVs not containing the targeting moieties should be removed 
from the preparation prior to use to prevent non-specific targeting if highest specificity is desired. 
In this sense exogenous targeting may have an advantage, as engineering EVs post isolation should 
affect the whole population equally, while endogenous targeting can be easier to perform once a 
stable cell line has been established. The validity of this conclusion still remains questionable as 
the universality of the methods mentioned above require further development and assessment by 
methods capable of high-throughput single EV analysis. 
 However, the clearance of non-modified EVs from blood is too high to achieve a 
reasonable exposure in targeted tissues (Kooijmans et al., 2016b). Improving the lifetime of EVs in 
circulation by reducing their nonspecific clearance is the most important aspect before even 
considering specific targeting of EVs. Especially macrophages contribute significantly to the rapid 
clearing of systematically administered EVs, leading to their accumulation in the mononuclear 
phagocyte system, especially in the liver and spleen (Imai et al., 2015). Elimination of macrophages 
(Imai et al., 2015) or inhibiting their scavenger receptor-mediated EV uptake with dextran sulfate 
(Watson et al., 2016) led to prolonged EV circulation time in mice and altered biodistribution 
patterns, with reduced accumulation in liver and spleen. Therefore, any therapeutic EVs should be 
modified to avoid recognition by macrophages, allowing them to reach their destination. 
Additionally, a strategy commonly used with liposome formulations involving poly (ethylene 
glycol) (PEG) coating (PEGylation) used to hide liposomes from phagocytes, has also been found 
applicable with EVs. PEGylation of EVs increased their circulation time, without affecting the 
biodistribution pattern (Kooijmans et al., 2016b). PEGylation of nanoparticles still has drawbacks 
that need to be taken into account in their formulations (Fang et al., 2017), as PEGylation hides 
the particles from other cells as well besides phagocytes, overcoming any targeting moieties they 
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may contain. An alternative strategy could be to overexpress the natural “don’t eat me” signals on 
the EVs, such as CD47, that are used by the immune cells to distinguish “self” from “not self” cells 
(Hayat et al., 2019). Indeed, it has been shown that EVs expressing CD47 are retained in circulation 
for a longer period than EVs from CD47-knockout cells (Kamerkar et al., 2017).  
 
1.2.2 Loading therapeutic cargo into extracellular vesicles 
Besides of the perspective on targeting, choosing the source of EVs for therapeutic applications is 
critical due to the differing innate content of EVs from different cell types that have differing 
effects on the cells once internalized. In contrast to targeting moieties that are found on the 
surface of EVs, therapeutic molecules can also be loaded inside of the EVs, making the selection of 
suitable EVs based on their cargo from a heterogeneous population of vesicles even more 
challenging. Cell lines enable production of EVs with desired biological cargo either through 
endogenous loading by transfection(Lang et al., 2017, Kim et al., 2018), overexpression of the 
cargo(Bolukbasi et al., 2012, de Jong et al., 2012, Mizrak et al., 2013), enrichment to EV biogenesis 
sites by guiding sequences in RNA(Batagov, Kuznetsov & Kurochkin, 2011, Batagov, Kurochkin, 
2013, Villarroya-Beltri et al., 2013, Bolukbasi et al., 2012), ubiquitination(Liu et al., 2009), linking 
them to lipid anchors(Kooijmans et al., 2016a) or fusion with EV-enriched proteins (Tian et al., 
2014, Sutaria et al., 2017). Besides endogenous cargo sorting, exogenous loading of biological 
molecules into EVs is challenging, given their large molecular size and ionic charge, which makes it 
difficult to transport them across a nonpolar lipid membrane surrounding the EVs. Experimental 
data regarding post-isolation loading of biomolecules has been focused mainly on small RNA 
species such as miRNA and small interfering RNA (siRNA) due to their functions in post-
transcriptional gene silencing and relatively small size, making them potent candidates for 
therapeutic cargo. Post-isolation loading of EVs requires generating temporary holes in the EV 
membrane by electroporation, sonication, extrusion, hypotonic dialysis or saponin treatment 
(Fuhrmann et al., 2015, Lamichhane, Raiker & Jay, 2015, Lamichhane et al., 2016, Kim et al., 2016, 
JC Bose et al., 2018). Similar strategy can be applied for hydrophilic small molecule drug loading. 
This approach is inefficient though, since there is no active driving force for the cargo to enter the 
EVs. In effect, it relies on random diffusion through small, temporary holes into small particles 
that, depending on their concentration, often occupy only a minute portion of the sample volume. 
Additionally, electroporation has been shown to cause aggregation of siRNA, which may hinder 
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loading efficiency if the method is not optimized properly (Kooijmans et al., 2013). Despite these 
issues, electroporation has been used in several studies for the preparation of EVs carrying various 
cargos, including siRNA, with promising therapeutic outcomes (Alvarez-Erviti et al., 2011, 
Kamerkar et al., 2017, Usman et al., 2018). Loading of hydrophobic molecules on the other hand 
can be accomplished easier, since they have high binding affinity to the nonpolar lipid membrane 
of the EVs, which also increases their solubility when compared to a simple water solution 
(Fuhrmann et al., 2015, Kim et al., 2016, Sun et al., 2010). Hydrophobic molecules can therefore 
be loaded simply by incubating them with EVs, although the process can be further enhanced by 
increasing the fluidity of the EV membrane, for instance by sonication (Kim et al., 2016). Nucleic 
acids such as siRNA can also be loaded onto EVs by incubation when they are crosslinked to 
lipophilic molecules such as cholesterol (Didiot et al., 2016, O’Loughlin et al., 2017). Small 
molecule drugs and nanoparticles can also be loaded into EVs by feeding them to the producing 
cells, from which they are carried over to the EVs they secrete (Sancho-Albero et al., 2019, Liu et 
al., 2019, Tang et al., 2012). Promising alternative methods have also been reported for loading 
EVs, for example by fusing them with liposomes, creating EV-liposome hybrid vesicles (Sato et al., 
2016, Piffoux et al., 2018). The liposome fusion method seems promising, given that liposomes can 
be prepared with precise lipid composition and content, including RNA, which could then be 
transferred to the EVs via fusion.  
 
1.2.3 Delivery of cancer therapeutics with extracellular vesicles 
The anti-cancer effect of EVs loaded with different chemotherapeutic drugs has been assessed in 
both in vitro and in vivo studies with promising results. EVs containing doxorubicin or the anti-
inflammatory compound curcumin could even cross the blood-brain-barrier carrying the drugs 
with them in mice with an intranasal delivery route (Zhuang et al., 2011) or in zebrafish with an 
intravenous injection (Yang et al., 2015). This resulted in reduced inflammation in the case of 
curcumin in a brain tumor model, leading to reduced tumor growth (Zhuang et al., 2011). 
Doxorubicin-carrying EVs also reduced the growth of brain cancer cells significantly (Yang et al., 
2015). Other drugs used with EVs include paclitaxel (Kim et al., 2016, Tang et al., 2012, Yang et al., 
2015) and cisplatin (Tang et al., 2012) that are commonly used in chemotherapy and reported to 
have increased cytotoxicity in cancer cells, when delivered with EVs targeted to these cells. 
Besides increasing the cytotoxicity of the drugs towards cancer cells, the EV-mediated delivery was 
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also found to reduce the harmful side-effects of the drugs. For example, the inherent 
cardiotoxicity hinders the use of doxorubicin in cancer therapy (Singal, Iliskovic, 1998), which is 
why a commercial formulation of doxorubicin packed in PEGylated liposomes (Doxil) is available. 
However, with EV-mediated targeted delivery to αv integrin expressing cancer cells, the 
concentration of doxorubicin in the heart could be limited as well without PEGylation (Tian et al., 
2014). Additionally, it was shown that the presence of gap junction protein connexin 43 in EVs 
with doxorubicin could further reduce its cardiotoxic effect without compromising its 
chemotherapeutic effect against cancer cells (Martins-Marques et al., 2016). EVs carrying 
doxorubicin and PTX could also overcome multidrug resistance in cancer cells, normally making 
these cells unaffected by the drug (Kim et al., 2016). With EVs, these drugs were able to bypass 
the P-glycoprotein-mediated drug efflux from the cells because of the endosomal delivery route, 
increasing the cytotoxicity of the drugs towards the resistant cells significantly. It has also been 
suggested that some EVs can be used to increase drug sensitivity of cancer cells without additional 
cargo or endogenous modifications (Ma et al., 2016, Liu et al., 2019, Jin et al., 2017). It was found 
that EVs secreted by tumor cells after UV irradiation can inhibit P-glycoprotein expression (Ma et 
al., 2016) and promote lysosome mediated trafficking of the chemotherapeutics to the nucleus, 
thus increasing the cytotoxicity of DNA binding drugs (Ma et al., 2016, Liu et al., 2019). 
Besides small molecule chemotherapeutics, EVs have also been used to deliver 
biomolecular cargo that affect cancer cells more specifically. Several miRNA and siRNA species 
have been identified with cancer suppressing activities, but their delivery requires a carrier that 
protects them from extracellular nucleases and helps them cross the cell membrane, a role that 
EVs can fulfill. Studies with such RNA species including miR-134 (O'Brien et al., 2015), let7 (Ohno et 
al., 2013) and siRNA (Alvarez-Erviti et al., 2011) have shown proof of concept for the effective anti-
cancer delivery of regulatory RNAs that show little to no adverse side effects. Therapeutic mRNA 
and protein cargoes have also been utilized, for example to sensitize cancer cells to specific drugs, 
such as cytosine deaminase that converts prodrug 5-fluorocytosine into cytotoxic 5-fluorouracil 
(Mizrak et al., 2013), providing another treatment option with little side effects. Another 
interesting strategy of EV-mediated therapy is to deliver oncolytic viruses that are able to 
specifically infect cancer cells, however the use of oncolytic viruses is limited by the strong 
immune response that they generate, leading to their elimination from blood circulation and thus 
preventing them from reaching cancer cells (Lawler et al., 2017). Additionally, viruses often 
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depend on specific receptors on the cell surface for binding and entering the cells, which may be 
absent from cancer cells. EVs could help circumvent these issues by providing both camouflage 
against the immune cells and complement proteins, while providing alternative modes of entry 
into the cancer cells. Although numerous studies have shown that viruses may use EVs to carry 
infective or non-infective viral cargo as reviewed by (Raab-Traub, Dittmer, 2017, van der Grein, 
Susanne G et al., 2018), only a few studies have focused on their therapeutic potential. A study by 
Ran et al. (Ran et al., 2016) showed that apoptotic cancer cells infected with an oncolytic 
adenovirus produce large infective EVs. These EV-encapsulated virions were resistant towards 
adenovirus neutralizing antibodies and were able to infect other cancer cells, even those lacking 
the CAR protein that adenovirus in question (isotype 5) requires for cell binding and 
internalization. Adeno-associated virus (AAV)-carrying EVs have also been explored as potential 
mediators for gene therapy, with the EV membrane protecting the virus from antibodies while 
achieving effective transduction in target cells and allowing retargeting of the virus by 
manipulating the EV surface (Maguire et al., 2012, György et al., 2017, Wassmer et al., 2017).  
 
Table 1: Assessment of studies evaluating EVs for cancer therapy. Example studies regarding 
different therapeutic EV preparation methods and their assessment are presented, with the 
respective preparation method, added targeting and cargo molecules and key outcomes listed. 
Reference 
Method for EV 
loading 
Active targeting Therapeutic cargo Outcomes 
(Alvarez-Erviti et al., 
2011) 
siRNA loading by 
electroporation into 
dendritic cell EVs 
Fusion of Lamp2b 
with peptides 
(RVG and MSP) 
targeting neural 
and muscle cells 
siRNA against BACE1, a 
gene involved in 
Alzheimer’s disease 
Significant in vivo 
BACE1 inhibition and 
amyloid plaque 
formation in the brain 
of mice after 
intravenous 
administration of 
BACE1 siRNA carrying 
RVG-targeted EVs. 
(Liu et al., 2019) 
UV irradiation  of 
donor cells followed 






mediated targeting of 
doxorubicin-carrying 




resistant breast cancer 
cells. 
The EVs increased the 
cytotoxic effect of 
doxorubicin in cancer 
cells, its blood 
circulation time and 
reduced its cardiotoxic 
side effects. 
(Fuhrmann et al., 2015) 





and hypotonic dialysis 
into EVs from several 
cell lines 
None 
Porphyrins of different 
water solubilities 
Hydrophobic porphyrins 
were loaded more 
effectively than 
hydrophilic. 
EVs increased their 
cellular uptake and 
toxic effect. 
Saponin and hypotonic 
dialysis treatments 






(Piffoux et al., 2018) 
PEG-mediated EV-
liposome fusion with 





Loading efficiency of 
mTHPC was close to 90 
% with liposome fusion, 
preserving the natural 
cargo of EVs as well. 
Transfer of PEG to EVs 





EVs delivered more 
mTHPC to cancer cells. 
(Yang et al., 2015) 
Incubation of bEND.3 
EVs with paclitaxel or 
doxorubicin at +37 °C 
None Paclitaxel and doxorubicin 
Successful doxorubicin 
delivery across the 
blood-brain-barrier in 
zebrafish embryos, with 
reduced tumor size. 
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(Ran et al., 2016) 
EVs from A549 cancer 
cells infected with 
oncolytic adenovirus 
None Oncolytic adenovirus 
Improved tumor 





(Gao et al., 2018) 
C2C12 myoblast-
derived EVs incubated 
with a CD63-binding 
peptide (CP05), linked 












oligomer (PMO), an 
antisense oligonucleotide 




mediated binding of 
EVs from different 
sources and attaching 
multiple moieties. 
Intravenous 
administration of EVs 
carrying both CP05-
M12 and -PMO lead to 
effective delivery of 




In conclusion, EVs provide a natural means to deliver various therapeutic cargo that can be 
adapted for the treatment of cancer. EVs can be loaded both with biological and synthetic 
molecules that possess targeting and therapeutic properties, enabling safer and more precise 
treatment of cancer in the future. However, the development of EVs for any therapeutic 
applications requires better understanding of the mechanism of EV-mediated cargo delivery and 









2 Aims of the thesis 
 
The objective of this thesis was to produce EVs carrying chemotherapeutic cargo and to examine 
their cytotoxic effect and mechanisms of cargo delivery into cancer cells in vitro. Autologous 
cancer cell-derived EVs were used as the model EVs for cargo delivery, with paclitaxel and an 
oncolytic adenovirus as the model therapeutics. More specific aims were as follows: 
 
Production of paclitaxel-carrying EVs by passive loading after EV isolation and determination of the 
cytotoxicity of the loaded EVs. (paper I) 
 
Examination of the EV-mediated mechanism of paclitaxel delivery by assessing its dependence on 
dose and surface proteins and by visualization by live cell microscopy. (papers I & II) 
 
Production and characterization of oncolytic adenovirus-carrying EVs by infecting cancer cells, 
followed by EV isolation from infected cell cultures. (paper III)  
 
3 Materials and methods 
 
3.1 Cell culture (I, II & III) 
Prostate cancer cell lines LNCaP and PC-3 and lung cancer cell line A549 were obtained from the 
American Type Culture Collection. All cell types were grown in T-175 flasks to 80 % confluence (I & 
III) or continuously in a two-chamber bioreactor (II) at +37 °C and 5 % of CO2. LNCaP cells were 
grown in Roswell Park Memorial Institute 1640 medium (RPMI), PC-3 and A549 cells in Dulbecco 
modified Eagle medium (F12k), both supplemented with 5 or 10 % (v/v) fetal bovine serum (FBS) 
and penicillin/streptomycin (100 units/mL penicillin and 100 μg/mL streptomycin). FBS was 
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vesicle-depleted by an overnight ultracentrifugation at 110 000 × g, followed by filtration with 
0.22 μm Steritop filter (Millipore) (I & III).  
II: The bioreactor upper compartment was filled with 750 mL of Ham's F-12 K medium for PC-3 
cells with non-depleted 10 % FBS, supplemented to a final concentration of 4.5 g/l glucose 
solution, and 100 units/mL penicillin/streptomycin. 15 mL of corresponding Ham's culture medium 
without FBS was used in the bioreactor's cell compartment to avoid FBS derived EVs.  
III: For infecting the cells, the medium with 5 % FBS was also supplemented with Ad5/3-D24-
GMCSF oncolytic adenoviruses at a concentration of approximately 30 particles per cell.  
 
3.2 EV isolation  
3.2.1 Differential centrifugation (I, II & III) 
EVs were isolated from conditioned medium using differential ultracentrifugation.  
I & II: First centrifugation at 2500 × g for 25 min at +4 °C to remove cell debris, followed by 20 
000 × g for 60 min at +4 °C to obtain the 20K MVs. The final supernatant was ultracentrifuged at 
110 000 × g for 1 h at +4 °C to obtain the 110K EXOs using rotor type 50.2Ti (Beckman Coulter).  
III: First centrifugation at 500 x g for 10 min at +4 °C to pellet cells, followed by 15 000 x g for 15 
min at +4 °C to pellet cell debris and ultracentrifugation at 150 000 x g for 2 h at +4 °C using rotor 
SW32Ti (Beckman Coulter) with 200 μL of 45% (w/v) iodixanol added to the bottom of the tubes as 
a density cushion. The bottom 3 mL of each tube was then pooled and concentrated further to 250 
μL with an Amicon Ultra-15 10 kDa centrifugal ultrafiltration unit (Millipore) at +4 °C.  
 
3.2.2 Iodixanol density gradient centrifugation (II & III) 
II: EV-pellets were loaded on top of a gradient prepared by overlaying 700 μl of 10 % iodixanol on 
top of 300 μl of 30 % iodixanol in 1.5 mL ultracentrifuge tubes. The samples were then 
ultracentrifuged in rotor TLA-55 with 170 000 x g for 3 h at +4 °C. The resulting visible EV-band in 
the 10 % and 30 % interphase was then collected and iodixanol was removed by ultrafiltration, 
filtering the samples three times with Amicon Ultra-4 10 kDa ultrafiltration units. 
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III: The density gradient was prepared with the diffusion method in a 13.5 mL ultracentrifuge tube 
by overlaying 4 mL of 45 % iodixanol with 4 mL of 25 % iodixanol buffered with Dulbecco’s 
phosphate buffered saline (DPBS)-2 mM MgCl2 and filling the rest of the tube with the same 
buffer. The tube was then incubated for one hour in horizontal position at +22°C. The samples 
mixed with iodixanol were then loaded through the gradient to the bottom of the tube and 
ultracentrifuged at 200 000 x g for 3 h at +4 °C with rotor SW41Ti (Beckman Coulter). After the run 
1 mL fractions were collected from the top of the tubes for further analyses, measuring their 
densities gravimetrically. 
 
3.2.3 Isolation of oncolytic adenoviruses (III) 
Ad5/3-D24-GMCSF virions were isolated from dead, infected A549 and PC-3 cells lysed by four 
freeze-thaw cycles and the cellular debris was removed by centrifugation with 5000 x g for 10 min 
at +4 °C. An iodixanol gradient was prepared into a 13.5 mL ultracentrifuge tube by layering 2 mL 
of 40 %, 3 mL of 25 % and 4 mL of 15 % iodixanol diluted in DPBS containing 2 mM MgCl2, with the 
15 % solution containing 1 M NaCl. Rest of the tube was filled with the virus-containing 
supernatant and ultracentrifuged at 200 000 x g for 2 h at +4 °C with rotor SW41Ti. The resulting 
band of viruses just below the 40 % and 25 % iodixanol interphase was collected and iodixanol was 
removed by ultrafiltrating the samples three times with DPBS, using Amicon Ultra-4 10 kDa 
ultrafiltration units at +4 °C.  
 
3.3 Immunoblot analysis of proteins (I, II & III) 
For western blotting, the protein markers present in cells and EVs were analyzed by loading equal 
protein amounts determined by a bicinchoninic acid (BCA) protein assay kit (Thermo Scientific). 
Whole cell lysates and EVs were prepared in 2 × Laemmli buffer (Bio-Rad) under non-reducing or 
reducing conditions depending on the antibodies used, separated with SDS-PAGE and the proteins 
were transferred onto a nitrocellulose membrane. For dot blot analysis, equal volumes of sample 
were blotted directly onto the membrane without prior separation. The membrane was then 
blocked with 5% (w/v) skim milk powder or BSA in Tris-buffered saline-0,1 % (v/v) Tween 20 (TBS-
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T) and then incubated with the respective primary antibody and secondary horseradish peroxidase 
(HRP)-linked antibody and imaged using either X-ray film or chemiluminescence imaging system.  
 
3.4 Nanoparticle tracking analysis (NTA) (I, II & III) 
Purified EV samples were analyzed by NTA using Nanosight model LM14 (Nanosight) equipped 
with blue (404 nm, 70 mW) laser and SCMOS camera. One 60 s video (III) or three 90 s videos (I & 
II) were recorded per sample and analyzed using NTA software 2.3 (I) or 3.0 (II & III). Viral samples 
were heat-inactivated at +95°C for 15 min prior to measurement.  
 
3.5 Preparation of Paclitaxel-loaded EVs (I) 
A 50 mM stock solution of Paclitaxel (PTX; Selleck Chemicals) was prepared by dissolving PTX into 
DMSO-isobutanol (1:1; Sigma-Aldrich). PTX-loaded EVs were prepared by incubating 1 × 108–
5 × 109 EVs/mL in 1 mL of 5 μM PTX-DPBS solution for 1 h at +22 °C. For trypsin-treated PTX-EVs, 
0,25 % trypsin was added to the samples and incubated for 30 min at +37 °C. Next, the samples 
were centrifuged at 170 000 × g for 2 h at +4 °C to pellet the EVs. The supernatant containing 
unbound PTX and trypsin was removed, and the EV-pellet was washed by suspending it in DPBS 
and pelleting it again. 
 
3.6 Fluorescent labeling of EVs (I & II) 
I: EVs were double-labeled with DiD lipophilic dye (Biotium) and OregonGreen-labeled PTX (OG-
PTX), (Invitrogen) to study the cellular distribution of PTX-EVs. First, the EVs were incubated for 1 h 
at +22°C with 5 μL of DiD solution per mL of EV suspension in DPBS. The unbound dye was 
removed by size exclusion chromatography (SEC) and the particle concentration was determined 
by NTA before labeling with OG-PTX. Next, 5 × 109 vesicles were incubated with 1 μL of OG-PTX 
(5 μM final concentration) in 1 mL of DPBS for 1 h at +22°C and purified by ultracentrifugation. For 
the co-localization studies of EVs and endosomes/lysosomes, the EVs were labeled with DiO 
lipophilic dye (Biotium). For the uptake experiments, EVs were labeled with 2 μg/mL of DilC18(5)-
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DS red dye (Life Technologies) for 20 min at +37 °C. Unbound dye was removed by pelleting the 
EVs twice by ultracentrifugation at 170 000 x g for 2 h at +4 °C. 
II: The 20 K MVs and 110 K EXOs were labeled and loaded for fluorescence lifetime imaging 
microscopy (FLIM) imaging by adding 7.5 μl of 1 mM PTX-OG to one milliliter of 20K MV/110K EXO 
suspension (20 K MV/110 K EXO particle concentration adjusted with DPBS to 
1.5 × 1010 particles/mL), and by incubating the suspension protected from light for 60 min upon 
shaking at ambient temperature. Following the incubation, the excess of PTX-OG was removed by 
centrifuging once with Optima MAX ultracentrifuge (MLA-130 rotor) at 110 000 g for 180 min, 
+22 °C. The 20 K MV/110 K EXO pellets were resuspended in 50 μl of DPBS before the application 
to the cells. After the PTX-OG labeling and loading, the MV membranes were labeled with DiD for 
confocal imaging by adding 1 μl of DiD to 1 mL of MV suspension (1010 particles/mL) and 
incubating for 30 min at +22 °C protected from light. Unbound DiD label was removed by 
centrifugation as described above. 
 
3.7 Viability assays (I & III) 
5000 cells per well were seeded in a 96-well plate and grown for two days before test sample 
administration. Cell viability was measured after 24 to 72 h by using the AlamarBlue viability assay 
according to manufacturer's instructions (Life Technologies). Fluorescence intensity was measured 
using VarioSkan Flash multireader (ThermoScientific) with 560 nm excitation and 590 nm emission 
filter settings. The viability values were then calculated from the fluorescence intensity values as a 
percentage of the control cells after subtracting the mean background values. 
 
3.8 Extracellular vesicle uptake assessment by flow cytometry (I) 
5 × 105 PC-3 cells and 3 × 105 LNCaP cells were seeded in 6-well plates at 70% confluence. The cells 
were then washed with DPBS and incubated with cell culture medium containing 108–
109 particles/mL of DiD-labeled 20K MVs or 110K EXOs. The cells were incubated with their 
autologous EVs for 1, 3, 6, 9, 12, 24, 32, and 48 h. Cells without EVs were used as negative 
controls. At each time point, the supernatant was removed and the wells were washed two times 
with DPBS. Cells were detached by trypsin treatment and fixed with 4% paraformaldehyde in DPBS 
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for 15 min at +37 °C. 10 000 events were analyzed by flow cytometry (Gallios, Beckman Coulter) 
using 638 nm laser for excitation, measuring the geometrical mean fluorescence intensity of the 
cells, representing cell-associated EVs. Data was processed by using FlowJo software 10.0. 
 
3.9 Fluorescence microscopy (I, II & III) 
3.9.1 Fluorescence microscopy of infected cells (III) 
For the apoptosis assay with Hoechst 33342 and propidium iodide (PI) staining, the cells were 
seeded in the wells of a 12 well plate and infected as described above. Every 24 hours following 
the initial infection the cells were stained with 100 μg/mL of both Hoechst 33342 (ThermoFisher 
Scientific) and PI (ThermoFisher Scientific), centrifuged with 1000 g for 5 minutes and inspected 
with EVOS FL Imaging System.  
For the immunofluorescence staining of adenovirus hexon coat protein, the cells were washed at 
every 24 hours following the initial infection with DPBS and fixed with 4 % (w/v) paraformaldehyde 
for 10 minutes at room temperature. The cells were washed with DPBS, blocked with 5 % BSA-TBS-
T, permeabilized with 0.1 % (v/v) Triton X-100 and stained with anti-Ad hexon antibody (8C4, 
Abcam) (1:2000 in 5 % BSA-TBS-T) and Alexa Fluor 488 goat anti-mouse secondary antibody 
(ThermoFischer Scientific) (1:200 in 5 % BSA-TBS-T) and inspected with EVOS FL Imaging System.  
 
3.9.2 Live cell confocal microscopy (I & II) 
Microscopy studies were performed using a TCS SP5II HCS A (Leica) confocal microscope and a 3I 
Marianas (3I intelligent Imaging Innovations) wide field microscope. On the imaging day, the cells 
were given the labeled EVs, free PTX, PTX-EVs or their combination. The cells were followed for 
the first 6 h, recording z-stacks covering the cells' thickness, and then additional images were 
taken after 24 and 48 h of incubation. The cell membranes were labeled with CellMask Deep Red 
Plasma membrane label and the lysosomes and endosomes with Lysotracker Red (Invitrogen, 




3.9.3 Fluorescence lifetime imaging microscopy (FLIM) (II) 
Fluorescence lifetime images were acquired using a fluorescence lifetime microscope MicroTime-
200 (PicoQuant, Germany) coupled to the inverted microscope Olympus IX-71 (Olympus, Japan). 
The pulsed laser diode LDH-P-C483 (PicoQuant, Germany) emitting at 483 nm (time resolution 
120 ps) was used for fluorescence excitation and the emission was monitored using 510 nm long 
pass filter. The SymPhoTime 64 software was used to calculate the lifetime map images. To gain 
more information on the lifetime changes, a region of interest (ROI) was selected and the 
corresponding fluorescence decay was extracted.  
 
3.10 qPCR analysis of viral DNA (III) 
DNA extraction and analysis were performed by extraction of the genomic DNA (gDNA) using 
NucleoSpin Tissue kit (Macharey-Nagel, Düren, Germany) according to the manufacturer protocol. 
qPCR was performed with equal volumes of gDNA samples using Maxima Probe/ROX qPCR Master 
Mix (ThermoFisher Scientific) and LightCycler480 system (Roche, Basel, Switzerland) with following 
cycling conditions: +95 °C for 10 min, 50 cycles of (+95 °C for 15 s, +60 °C for 1 min).  
DNA concentrations (in arbitrary units) for comparative analyses were then calculated from the 
acquired Ct-values with the formula  
[DNA] = 2-Ct, 
and used to compare paired samples. 
 
3.10.1 Proteinase K and DNase treatments 
In order to examine the whether the DNA was inside IEVs, the samples were treated with 
proteinase K to free any DNA inside virus capsid, followed by degradation with DNase I. A sample 
of purified free virus was used as a control for the treatment. Samples were treated with 1 mg/mL 
proteinase K (ThermoFisher Scientific) for 2h in +37 °C. Proteinase K was inactivated by heating 
(+90 °C for 5min) followed by addition of complete protease inhibitor cocktail (Roche). 5 U of 
DNase I (ThermoFisher Scientific) was then added and samples incubated for 1h in +37 °C. 
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Treatment was ended by addition of 1:10 volume of EDTA and incubation of 10 min in +65 °C. The 
samples were then used for gDNA extraction as described above. 
 
3.11 Transmission electron microscopy (TEM) (I & III) 
3.11.1 TEM of EVs (I) 
4 μL of EV samples were added onto purified EM grids, washed with distilled water, negatively 
stained with 2% aqueous uranyl acetate (System Biosciences, Mountain View) for 2 min and dried 
out protected from light for 20 min. The samples were analyzed by TEM (FEI Tecnai 12).  
 
3.11.2 TEM of cells treated with infected cell-derived extracellular vesicles (III) 
200 000 cells were seeded on top of EM grade 0.1 mm coverslips in and treated with IEV samples. 
After one or two days of incubation the cells were fixed with 2 % (v/v) glutaraldehyde for 20 
minutes at +22°C. The cells were washed two times with 0.1 M Na-phosphate buffer pH 7.0 and 
osmicated with 1 % OsO4 in 0.1 M NaCac buffer for 1h at RT. The samples were washed and 
dehydrated with ethanol, dipped in acetone and covered with Epon for 2h at RT and 18h at +60°C. 
60 nm sections were cut from the samples onto pioloform grids and post-stained with 0.5 % uranyl 
acetate for 30min and 3 % lead acetate for 1min. Imaging was performed with Jeol JEM 1400 
electron microscope (Akishima, Tokyo, Japan) operated at 80 kV. 
  
3.11.3 Cryo-TEM of EV-/IEV-samples (I & III) 
Iodixanol or sucrose was removed by ultrafiltration with Amicon Ultra-0.5 10 kDa ultrafiltration 
units from fresh, non-frozen samples (III). The vitrified samples were prepared with a Leica EM GP 
vitrification device from 3 μL aliquots of each sample on freshly prepared sample grids and 
observed in a JEOL JEM-3200FSC field emission Cryo-TEM (I) or FEI Talos Arctica microscope (III). 







4.1 The effect of paclitaxel loaded extracellular vesicles on cancer cell 
viability was dose-dependent 
EVs were isolated from two prostate cancer cell lines (PC-3 and LNCaP) with differential 
centrifugation into two populations based on their sedimentation speeds (20K MVs and 110K 
EXOs) and loaded with PTX by incubating at room temperature. Because PTX is a strongly 
hydrophobic compound, it was hypothesized that it would passively bind to the lipid membrane of 
EVs. Since there was much uncertainty in the results derived with LNCaP cells due to the cells’ 
sensitivity to the cell culture procedures during viability assays, the results and discussion is 
focused on PC-3 cells, while the results obtained with LNCaP cells followed a similar trend. 
According to UPLC measurements of PTX concentration, approximately 10 % of the PTX in solution 
was bound to the EVs in the final preparation with no significant differences caused by the type or 
concentration of EVs during loading. The PTX-EVs were then given to their originating cells, and 
their cytotoxicity was assessed in a dose-dependent manner after 24 and 48 hours of incubation 
and compared to free PTX corresponding to the loading conditions (Figures 5A and B). While the 
presence of residual free PTX in the samples cannot be excluded due to leaking from EVs or as a 
result of aggregation during washing away of free drug, the resulting cytotoxicity profiles revealed 
several differing characteristics of PTX-EVs compared to free PTX. Firstly, the highest 
concentrations of PTX-MVs had reduced cell viability after 48 hours compared to the free PTX 
control (Figure 5B). In other words, MVs increased the cytotoxic effect of PTX. This effect was not 
apparent at the 24-hour time point, where the cell viability was higher in the PTX-MV groups 
compared to the free PTX control, suggesting an alternate, delayed mechanism of action of MV-
mediated PTX delivery. In contrast, PTX-EXOs did not increase the cytotoxicity of PTX, remaining 
slightly less effective than the free PTX control. The lowest concentrations of PTX-EXOs actually 
increased cell viability, which peaked at the 48-hour time point. A much lesser viability enhancing 
effect was also observed with the lowest concentrations of PTX-MVs as well. This became 
apparent only when the concentration of PTX was low enough. Finally, the dose dependences of 
both PTX-EV types followed a similar s- curve type in cytotoxicity, with a saturation point around 
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the 108 EVs/mL concentration, where cytotoxicity was most strongly influenced by changes in 
concentration. 
Next, to maximize the cytotoxicity of PTX-EVs, the amount of EVs was reduced during 
the loading of PTX to the saturation point concentration of 108/mL observed in viability assays. 
This lead to the increase of PTX per vesicle by a factor of 50 in the final preparation, designated as 
“high load-PTX-EVs” (HL-PTX-EVs) in contrast to “low load-PTX-EVs” (LL-PTX-EVs) in figure 5, after 
washing and improved the cytotoxicity of PTX-EXOs, while the cytotoxicity of PTX-MVs was 
unaffected (Figures 5C and D). HL-PTX-EXOs with more PTX per vesicle than in LL-PTX-EXOs were 
as effective as HL-PTX-MVs, also with reduced viability enhancement in the lower dose group 
compared to the EXOs with less PTX in Figure 5A. The viability enhancing effect of EVs was 
confirmed with MVs and EXOs without PTX (Figures 5E and F), where a similar pattern of viability 
increase was observed in both groups, confirming that it is a property of EVs related to the EV 
subtypes. Additionally, the dependence of the EV-mediated PTX delivery on EV surface proteins 
was assessed by removal of those proteins by trypsin treatment. The effect on the cytotoxicity of 
HL-PTX-EVs caused by the trypsin treatment (Figure 6) suggested that EV-mediated PTX delivery 
was mostly independent on the EV surface proteins, since their removal did not affect the 
cytotoxicity of HL-PTX-EXOs, although HL-PTX-MVs were slightly less cytotoxic at lower 
concentrations (Figures 6A and B). A similar effect was found, when comparing the uptake of 
labelled EVs by flow cytometry (Figures 6C and D). Non-treated EVs from both cell lines displayed 
similar accumulation patterns over 24-hours (Figure 6C), but trypsinization lowered the amount of 
MV uptake, while EXOs were unaffected (Figure 6D). Cryo-TEM analysis of 20K MVs did not show 
any structural changes caused to the vesicles by the treatment (Figures 6E and F), while western 
blot analysis showed substantially diminished signal from EV membrane proteins CD9 and CD63 
(Figure 6G), suggesting that the observed difference in cytotoxicities was due to the cleavage of 
proteins, and not structural damage to the EVs. 
Overall, these results show that autologous EVs are able to bind PTX in solution and 
carry it into prostate cancer cells. This delivery mode can enhance the cytotoxicity of PTX but the 




Figure 5: Dose-dependence of EV-mediated PTX delivery. PC-3 derived EVs were incubated with PC-3 cells 
and viability of the cells was measured as percentage compared to mock control cells after 24, 48 and 72 h. 
(A and B) 110K EXOs (A) and 20K MVs (B) were loaded with PTX at 1 nmol per 109 particles (LL-PTX-EXOs 
and LL-PTX-MVs)) and added to cells at different particle concentrations with 5 μM PTX as the control. (C 
and D) the cytotoxicity of 110K EXOs (C) and 20K MVs (D) was assessed after loading them with PTX at 5 
nmol per 108 particles (HL-PTX-EXOs and HL-PTX-MVs). 20K MVs seemed to more sensitive to the 
treatment, as was demonstrated by slightly reduced cytotoxicity and uptake rate. (E and F) The 




Figure 6: The effect of trypsin treatment on the EVs and their drug delivery properties. (A and B) HL-PTX-
EXOs (A) and HL-PTX-MVs (B) were loaded with PTX and their surface proteins were removed by trypsin 
treatment. They were then added to PC-3 cells and their effect on cell viability was compared to non-
trypsinized control EVs. (C and D) PC-3 and LNCaP EVs were labeled with DilC18 (5)-DS and their cellular 
binding and uptake was measured as a function of incubation time with flow cytometry. In C, EV subtypes 
from both cells are compared to each other. In D, PC-3 EVs were trypsinized and compared to non-treated 
controls. (E and F) Cryo-TEM images of 20K MVs before (E) and after (F) trypsin treatment. G: The effect of 
trypsin treatment on EV surface proteins CD9 and CD63 was assessed by western blotting. 
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be relevant because of this, since a smaller load of PTX per vesicle was unable to reach its full 
cytotoxic potential in the case of EXOs, while a higher PTX load was clearly more effective. The 
surface proteins of EVs appear to have little effect on cellular internalization, though the uptake of 
 
4.2 Extracellular vesicles carry paclitaxel into PC-3 cells via endocytosis and 
display subtype-dependent differences in their drug release mechanisms 
To study the uptake mechanism of PTX-EVs, fluorescently labelled EVs and PTX were used to track 
their intracellular trafficking with confocal live cell imaging (Figure 7). First, labelled EVs without 
PTX were observed to co-localize strongly with lysotracker, a dye used to label members of the 
endosomal pathway, suggesting that EVs were taken up via endocytosis (Figure 7A). EVs carrying 
fluorescent PTX (PTX-oregon green, PTX-OG) were found to carry PTX-OG with them into the cells 
with partially similar staining patterns (Figure 7B). It should be pointed out however, that 
fluorescent labels used to label EVs (DiD) and PTX-OG can form aggregates that co-sediment with 
EVs during post-labeling washes or leak from the EVs and affect the observed dye distribution, 
given that they are lipophilic compounds capable of binding and diffusing through the plasma 
membrane of cells (Dominkuš et al., 2018). In addition to the spot-like staining of the EVs, in some 
cells the PTX-OG had also spread into the cells’ cytoplasm and displayed a much higher total 
fluorescence intensity in the cells, respectfully designated here as “low intensity” (LI) and “high 
intensity” (HI) cells. While free PTX normally binds to and stabilizes the microtubules, as observed 
in HI-cells, causing its cytotoxic effect (Singla, Garg & Aggarwal, 2002), the EV-mediated 
endosomal delivery route seemed to alter the subcellular distribution of PTX in LI-cells, suggesting 
that the results are not an artefact of leaked or aggregated PTX-OG. In LI-cells PTX-OG was 
restricted into the endosomal network without compromising its cytotoxic effect and killing the 
cells within 24 hours. To further elucidate the observed mechanism of EV-mediated PTX delivery, 
the trafficking of PTX-OG inside PC-3 cells was studied by live cell fluorescence lifetime imaging 
microscopy (FLIM) (Figure 8). Since fluorescence lifetime is dependent on the immediate 
environmental conditions surrounding the fluorescent molecule, such as pH, viscosity or polarity, 
FLIM gives information about the changes of environment that PTX-OG goes through when it is 
delivered from EVs to cells and until the cells die. Free PTX-OG passed through the cell membrane 




Figure 7: Confocal microscopy analysis of the uptake of EVs and EV-mediated PTX-OG delivery in 
PC-3 cells. (A) The co-localization of EVs and endo-lysosomal compartments in cells was examined 
with DiO-labeled EVs and LysoTracker Red (LT), showing significant co-localization of the two dyes 
after 24 hours. (B) The cellular distribution of EV-delivered PTX-OG (green) was examined every 4 
hours after 2 hours of incubation with the PTX-OG-EVs. The cells’ plasma membranes were stained 




unchanged throughout the imaging, there was a small change towards shorter average 
fluorescence lifetime (<τ > α) after 4 hours of incubation as indicated by a shift to a greener color 
in the FLIM images. This result suggests a change in the immediate environment of the 
microtubules, caused by the binding of PTX-OG. PTX-OG carried by EVs displayed two distinct 
patterns of cell staining and fluorescence lifetime profiles. Cells treated with 110K EXOs carrying 
PTX-OG were only found to display LI-cells (Figure 8B), while both LI- and HI-cells (Figure 8C) were 
found in samples treated with the 20K MVs. In HI-cells the staining after 2.5 hours resembled that 
caused by free PTX-OG (Figure 8A) in pattern, <τ > α and intensity. LI-cells displayed a completely 
different pattern, with a shorter <τ > α and a more spot-like staining in the cytoplasm, instead of 
the fibril shapes of microtubules. Confocal microscopy imaging revealed that this spot-like pattern 
corresponded to the endosomal network (Figure7A). Taken together, the PTX-OG in HI-cells 
appeared to avoid or escape accumulation in the endosomal pathway much faster than in LI-cells, 
indicating a possibility for an alternative uptake pathway in HI-cells. 
 Analysis of the fluorescence lifetime signal revealed that it consisted of two 
components with lifetimes of approximately 4 – 4.3 ns (τ1) and 1 – 2.7 ns (τ2). The lifetime each 
component and their portions of the total fluorescence signal changed over time in the cells as 
shown in Table 2 and Figure 9. The observed changes could be divided into three phases (1 – 3 in 
figure 9) for both components: first (1) the fluorescence lifetime rose rapidly during the initial 2 
hours of the measurement as PTX-OG-EVs accumulated into the cells. At the peak of the first 
phase, free PTX-OG and HI-cells had similar, higher fluorescence lifetimes than LI-cells, though the 
difference was most notable in τ2. Next (2), the fluorescence lifetime started to decline, for 
approximately 10 hours, representing a change in the environment of PTX-OG. This phase could be 
interpreted to reflect the release of PTX-OG from the EVs or the progression of PTX-OG-EVs in the 
endosomal network in LI-cells and the changes occurring in the microtubules of free PTX-cells and 
HI-cells. Finally, (3), as the cells died, the fluorescence lifetimes of PTX-OG rose to a similar level in 
all sample types, signifying that the cellular environment was similar in all apoptotic cells, 





Figure 8: FLIM imaging of PTX-OG distribution in PC-3 cells. Fluorescence lifetime of PTX-OG was measured 
in cells at different time points after adding free PTX-OG (A), or PTX-OG EVs (B and C). In B, a “high 
intensity” cell is presented, as identified in 20K MV experiments. In C, a “low intensity” cell is presented, 
identified with both types of EVs. The color of each pixel in the FLIM images correlates with the average 
fluorescence lifetime in the corresponding spatial location as follows: 2.0 ns  4.5 ns. 







Table 2. Fluorescence lifetime components τ1 and τ2, the portion a2 of τ2, and average 
fluorescence lifetime, <τ>α, for Ptx-OG in each experimental setup, with HI- and LI-cells separately. 
Cell samples Interaction time τ1 (ns) τ2 (ns) a2 (%) <τ > α 











































Figure 9: Average fluorescence lifetimes of the two components of PTX-OG fluorescence in PC-3 cells. 
Fluorescence lifetimes of PTX-OG were measured in cells as a function of time, with average lifetimes for 
components τ1 (a) and τ2 (b) presented separately for each condition. 
 
In summary, FLIM was used to confirm that there was a significant difference in PTX-OG delivery in 
recipient PC-3 cancer cells caused by the EV-mediated delivery compared to the diffusion of free 
PTX-OG, as indicated by τ2. Based on the distribution of τ1 in cells and its consistency, it appears to 
reflect PTX-OG bound to the plasma membrane and possibly other cellular membranes, while the 
value of τ2 was clearly more dependent on the delivery route and it was also more prominent in LI-
cells than in HI-cells. Therefore, τ2 can be more useful to follow the trafficking of PTX-OG and 
predict the mechanisms involved, where lower or higher values could indicate an environment 
corresponding to the endosomal network or values binding to microtubules, respectively.  
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4.3 Extracellular vesicles as carriers of oncolytic adenovirus 
Next, it was examined whether EVs isolated from cancer cells infected with an oncolytic 
adenovirus could be used as carriers of the virus, and if they displayed any significant differences 
compared to normally secreted EVs. For this purpose, A549 and PC-3 cancer cells were infected 
with Ad5/3-D24-GMCSF virus (Koski et al., 2010) and the EVs were collected and purified every 24 
hours for five days (D1 – D5) by iodixanol gradient centrifugation. As the results from both cell 
lines were nearly identical in most experiments, only the data from PC-3 cells is presented in such 
cases. The density fractions from D1 – D5 were analyzed for cytotoxicity, nanoparticle-, total 
protein-, adenoviral hexon surface protein- and adenoviral DNA concentrations to identify and 
characterize the EVs from infected cells (IEVs) for viral cargo and its functionality. Given that EVs 
have a characteristic range of density that is lower than the density of adenoviruses (1,21 g/mL) in 
iodixanol (Dormond et al., 2010), IEVs were expected to be separated effectively from any free 
virions present in the cell culture supernatant into fractions of lower density. Cytotoxicity assay of 
the density fractions revealed that virions isolated from infected cells indeed migrated to the 
expected density in iodixanol gradient (fractions 7 – 10) (Figures 10A and B). However, in addition 
to these virion-containing fractions, with IEV samples also lighter fractions (2 – 6) were found to be 
cytotoxic (Figures 10C and D). TEM imaging of the cells treated with fraction 4 revealed that they 
did contain virions in their nuclei, confirming viral infection caused by the IEV fraction (Figures 10E 
– G). The most striking observation, however, was that the infective IEVs appeared as early as one 
day after the initial infection (D1), which was prior to the lytic release of adenoviruses, denoted as 
the classical pathway that the adenovirus uses to spread (Gros, Guedan, 2010). As shown in figure 
11, after being infected with the virus, the cells start to show early signs of apoptosis only after D2, 




Figure 10: Cytotoxicity assessment of IEV fractions. (A) The buoyant density of free virions isolated 
from cells was determined with a cytotoxicity assay from each fraction with A549 cells. Only 
fractions 7 – 10 were found to by cytotoxic. (B) Table of densities for each fraction collected. (C) 
cytotoxicity of IEV iodixanol density fractions. IEVs were collected from PC-3 cells every 24 hours 
for five days (D1 – D5) after initial infection and purified with iodixanol density gradient. 
Cytotoxicity of each fraction was determined with autologous cells with an equal volume from 
each fraction. (D – F) TEM imaging of A549 cells after 48h with IEV D3 fraction 4 (D), PC-3 after 24h with 
IEV D3 fraction 4 (E) A549 after 48h with IEV D1 fraction 4 (F). White markers indicate the nuclear 




Figure 11: Progress of apoptosis in infected cells. The progress of apoptosis in A549 and PC-3 cells during 
D1 – D5 was monitored by fluorescence microscopy using Hoechst 33342 and propidium iodide (PI) 
staining. Nuclear condensation is observed earliest at D2 suggesting early apoptosis, leading to cell 
rounding at D3 and permeation of PI at D4 to D5, which are markers for late apoptosis. 
 
The distribution of IEVs in the gradient corresponded to the normal EVs secreted by 
these cells as indicated by NTA assay of the fractions (Figure 12A). The IEV and EV fractions 
contained also comparable amounts of protein per particle (Figure 12B) and they had similar size 
distributions (Figure 12C), suggesting no significant differences in their basic structures. Cryo-TEM  
imaging of the IEV fractions showed vesicle morphology typical for EVs (Figure 12D), with no 





Figure 12: Physical characterization of PC-3 IEVs. IEV fractions 1 – 6 were analyzed with NTA and 
total protein assay to determine relative particle concentrations (A) and protein per particle ratios 
(B) in each fraction and the size distribution of particles, with the result of fraction 4 as a 
representative fraction (C). Cryo-TEM imaging was used to visualize IEVs collected after five days 
of uninterrupted IEV secretion in cells (D), showing vesicle structures typical to EVs.  
 
samples with anti-adenoviral antibodies still indicated a presence of viral proteins in the IEV 
samples (Figure 13). A dotblot analysis of each fraction from D1 – D5 (Figure 13A) showed very 
little or undetectable amounts of adenoviral hexon protein in D1 and D2 samples, with a 
significant increase across all fractions after D3, following the apoptotic cell lysis. Hexon protein 
was present in the IEV fractions with a consistent peak at fraction 4, though at lower 
concentrations than in the free virus fractions 7 – 10. Western blot analysis of IEVs with a 
polyclonal anti-adenovirus antibody showed that compared to infected cells, IEVs are enriched in 
hexon over other viral proteins (Figure 13B). Incubating IEVs with this antibody also neutralized 
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their infectivity completely (Figure 14A), suggesting that the proteins on the outer surface of IEVs 
are critical to their function. Also, unlike free virions, IEVs were found to be sensitive to detergent 
treatment, again losing their infectivity (Figure 14B), indicating that the infectivity of IEVs is 
independent of viral capsids that would endure detergents. 
 
Figure 13. Characterization of viral proteins associated to PC-3 IEVs. (A) The expression of adenoviral hexon 
protein was assessed in PC-3 IEV fractions from all time points D1 – D5 by dot blotting and normalized 
against the highest expression level, usually at fraction 8 of D5. D1 samples did not produce a high enough 
signal to be measured. (B) The viral protein composition of pooled IEV fractions (1 – 6) from each time 
point was compared to corresponding cell lysates by western blotting with a polyclonal anti-adenovirus 
antibody, with α-tubulin examined as a housekeeping protein. Compared to cell lysates, IEVs start to 
express observable amounts of viral proteins after D2 and they are enriched with hexon protein (110 and 
130 kDa bands). In cells, the expression of viral proteins also increased over time, as indicated by a relative 




Figure 14. IEV-mediated infectivity is sensitive to adenovirus neutralizing antibody and detergent 
treatment. IEVs and adenovirus control samples (Ad1 high and Ad2 low concentration) were treated with 
an adenovirus neutralizing antibody (A) or detergent (B), followed by a cytotoxicity assay. Compared to 
non-treated controls, IEVs lost their infectivity in almost all of the cases (A549 D5 samples partially survived 
the detergent treatment), while adenovirus controls were only neutralized by the antibody. 
 
The adenoviral DNA content of IEVs and other fractions was also analyzed by qPCR 
(Figure 15), confirming the presence of viral DNA in the IEV fractions 1 – 6 in addition to the free 
virus fractions (7 – 10) (Figure 15A). The distribution of viral DNA across the IEV fractions appeared 























Figure 15. Characterization of IEV-associated adenoviral DNA. The concentration of adenoviral DNA was 
estimated with RT-PCR in A – D, with primers against adenovirus E4 gene (or human GAPDH for comparison 
in D). Results with E1A primers provided near identical results. (A) The adenoviral DNA concentration was 
assessed in all PC-3 sample fractions from different time points and normalized for each time point 
separately to assess its distribution across the gradient. (B) The amount of adenoviral DNA was compared 
to the particle concentration in PC-3 IEV fractions to estimate DNA per particle ratios. (C) The total amount 
of IEV-associated adenoviral DNA was calculated for different time points in pooled fractions 1 – 6 and 
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normalized against the highest concentration. (D) Adenoviral virions (Ad) and IEVs were treated with 
proteinase K and DNase I in different conditions to assess the localization of their DNA content. Treatments 
were performed with or without proteinase K at +37 °C or +55 °C to cleave shielding proteins, followed by 
DNase I treatment to digest the DNA. The results are reported as remaining DNA compared to pre-
treatment concentrations. 
 
which was contrary to hexon and particle distributions that had peaks at fraction 4 (Figures 12A 
and 13A). This relationship was also apparent when the viral DNA concentration was compared to 
the particle concentrations, showing that particles with higher density were associated with more 
DNA (Figure 15B). The viral DNA was also shown to contain near equal amounts of genes E1A and 
E4, located at the opposite ends of the adenoviral genome, suggesting that the whole genome was 
present in IEVs. The total amount of viral DNA in the IEV fractions increased along the progression 
of infection from D1 to D5 (Figure 15C) and like cellular DNA in the IEVs, it was partially resistant to 
the enzymatic treatment used to cleave DNA in free virions (Figure 15D). Approximately 70 – 95 % 
of the viral DNA associated with IEVs was degraded as a result of different variations of the 
proteinase K treatment followed by DNase, suggesting that most of the DNA was bound to the 
outer surface of IEVs. Compared to free virions, which required proteinase K treatment at +55 °C 
to release their DNA for degradation, in IEVs the differences between treatment temperatures of 
37 °C to +55 °C or even total absence of proteinase K did not cause a large difference in DNA 
degradation. Taken together, these results indicate that the DNA associated to IEVs is not 
protected by a durable protein capsid as Ad virions have, but most of it is exposed on the outer 
surface of the vesicle and rest of it is inside, where it is protected from both the enzymes, even at 
+55 °C. 
Taken together, cancer cells infected with an oncolytic adenovirus secreted IEVs that 
carried viral cargo and were able to transmit it to neighboring cancer cells, spreading the infection. 
These IEVs were secreted already at the early stages of the infection, before the apoptotic release 
of virions, and the amount of viral cargo they carried reflected the stage of the infection. 
Additionally, while IEVs were similar to the normal EVs secreted by these cells in their physical 
properties, some density related heterogeneity existed among the IEVs, with more viral DNA being 






5.1 Autologous cancer cell-derived extracellular vesicles are effective as 
carriers of chemotherapeutic cargo 
In this thesis, the use of EVs from different cancer cells as an autologous delivery system was 
examined with PTX and oncolytic adenovirus as the model therapeutic cargo. The hypothesis was 
that since cancer cells use EVs to communicate between each other, the therapeutic cargo of EVs 
would also be internalized by the cells during EV uptake. This kind of autologous drug delivery 
approach could help circumvent the problem caused by the heterogeneity of tumors, the fact that 
a single drug targeting moiety may not recognize all of the cancer cells of a tumor because they 
express different phenotypes. Additionally, cancer cells provide a pathway for the preparation of 
oncolytic virus-carrying IEVs that cannot be applied with normal cells without modifying the virus 
or the cells by genetic engineering, since oncolytic viruses by definition cannot replicate in healthy 
cells. In these studies, all of the PTX-EV or IEV preparations were found to be functional, i.e. they 
were able to carry the cargo into the cancer cells and cause a cytotoxic effect. In the case of PTX-
loaded EVs, the cytotoxic effect of PTX was even enhanced, when the ratio of PTX per EV was 
optimized. This enhancing effect has been reported by others as well, with the use of different 
drug loading methods and drugs (Kim et al., 2016, Tang et al., 2012, Yang et al., 2015), adding to 
the accumulating evidence for EVs having potential drug delivery capabilities. However, as found 
here and by others, autologous cancer cell-derived EVs also possess an innate viability enhancing 
effect in recipient cancer cells (Ozawa et al., 2018, Raimondo et al., 2015), as well as other cancer 
promoting effects discussed in section 1.1.4. This viability enhancing effect is exactly the opposite 
to the desired effect of killing cancer cells, and makes direct applications based on cancerous EVs 
unsafe in practice. In future it might be possible to neutralize the cancer promoting cargo of these 
EVs by e.g. removing it through temporary pores by methods described in section 1.2.2 or by 
inactivating it by ionizing radiation (Eldh et al., 2010). Neutralizing the cargo would, however lead 
also to the loss of any biological therapeutic molecules, such as Ad DNA or anti-cancer RNAs. 
Additionally, cultivating a patient’s cancer cells for ex vivo EV-production poses a formidable 
challenge in itself. Therefore, the best way to take advantage of the cancer cell-derived EVs in 
practice is to learn from them and mimic them: identify the most critical surface structures and 
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reproduce them in a well-characterized, safer EVs for cancer targeted delivery. In study (I), it was 
shown that trypsinization of the PTX-EVs was able to diminish their cytotoxic effect only partially, 
suggesting that the EV surface proteins are not critical for their uptake, and that the cells must 
also be able to bind to something else in their lipid membrane. Glycolipids represent a strong 
targeting candidate given that heparan sulfate competitively inhibits the uptake of most EVs (Atai 
et al., 2013), blocking their glycans from interacting with the cell surface, although other glycan 
structures besides heparin sulfate, such as those in ganglioside GM2 have been identified as 
ligands in lipid-protein signaling (Kundu et al., 2016), and PS has its own receptors as well (Segawa, 
Nagata, 2015).  
While cell binding followed by EV uptake in general is crucial for the delivery of any 
cargo, subcellular trafficking of the cargo may also be important regarding its activity in the 
recipient cell. It has been shown that the protein content of EVs separates the lipids into the 
lysosomes from once inside the cell (Tian et al., 2010). However, it is currently unclear, if there are 
any subcellular targeting moieties on the EVs that would guide them into specific cellular 
organelles besides the endosomal network. To release any intraluminal cargo, the internalized EVs 
would either have to fuse with the endosomes, or have their membrane degraded. Any cargo that 
is bound to the outer surface of the EVs would also have to detach from the EVs in the endosome 
in order to reach its relevant subcellular destination. In any case, the EVs would lose their 
structure and cargo, with their components being either degraded or sorted into their respective 
subcellular destinations. Therefore, subcellular targeting of their cargo should be possible by 
modifying the cargo molecules themselves as described by Sakhrani and Padh (Sakhrani, Padh, 
2013). In studies (I) and (II), the PTX-OG in PTX-OG-EVs was shown to be internalized into the 
endosomal pathway in LI-cells and to bind to the microtubules in HI-cells, killing the cells 
regardless of the final subcellular destination of the drug. This observation of different localization 
of PTX-OG is contrary to the main reported mechanism for PTX cytotoxicity, which is based on 
stabilizing microtubules inhibiting depolymerization. The contradiction could be explained if PTX 
bound to and inhibited also another target besides microtubules. It has been shown that PTX can 
bind to apoptosis regulator Bcl-2 (Ferlini et al., 2009), located on the membranes of mitochondria, 
endoplasmic reticulum and nuclear membrane (uniprot database). Given that the endosomal 
trafficking also occurs to the trans-Golgi network, it would enable PTX to spread into virtually any 
cellular organelle through intracellular vesicle trafficking (Elkin, Lakoduk & Schmid, 2016). In any 
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case, PTX-OG was shown to both follow the endosomal network in the LI-cells and to escape it 
within 2.5 hours in the HI-cells, suggesting that the sorting of EV cargo may be altered in HI-cells, 
or that certain EVs that behave differently were enriched into them. It has been suggested that 
the cell cycle phase of the recipient cells affects their EV internalization (Lazaro-Ibanez et al., 
2017), however there must also be some difference between 20K MVs and 110K EXOs, since HI-
cells were only observed in the former. As presented in study (II), FLIM provided a powerful 
addition to the methods for studying EV intracellular trafficking, giving more detailed information 
about the cellular environment of PTX-OG, than conventional fluorescence microscopy methods. 
In future studies, FLIM can be used to determine the changes in environment that EVs go through, 
and what effects do these changes have regarding the fate of EVs in cells. 
 
5.2 Extracellular vesicles divided by their density into subtypes have 
different cargo profiles and delivery mechanisms 
The 20K MV fraction used in the experiments, where HI-cells were identified with PTX-OG staining, 
was separated from 110K EXOs based on sedimentation speed. Given that the size distributions of 
these two populations were overlapping, the higher sedimentation speed of 20K MVs suggests 
that they have a higher density. From the cryo-TEM images of 20K MVs it can be determined that 
most of the vesicles are multilamellar, i.e. they contain more than one lipid bilayer. The apparent 
enrichment of multilamellar EVs in the 20K MV samples would explain the increase in density and 
possibly also the decrease in protein per particle ratio that was reported in both studies I (Figure 
1E) and II (Figure S3), caused by reduced space for soluble cargo. The same explanation may also 
be related to the observed reduced viability enhancing effect in study I (Figures 4 and 5), when 
comparing 20K MVs to 110K EXOs, if the latter contained more soluble cargo, including different 
RNA species, metabolites and soluble proteins. The western blot analysis of these two sample 
types in figure 1F seems inconclusive though, showing no apparent trend regarding soluble or 
membrane protein enrichment in either population compared to the other. Multilamellar EVs 
should also have an increased capacity to bind hydrophobic compounds such as PTX, though again 
no notable differences could be observed in study (I). While the hypothesis of enrichment of 
multilamellarity in 20K MVs still seems possible, it requires validation in future studies and its 
implications to cargo delivery are difficult to predict. If the release of EV cargo in the endosomes is 
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dependent on the fusion of the EV outer membrane with the endosomal membrane, then in the 
case of multilamellar EVs, it would lead to the release of their inner vesicles into the cytoplasm, 
where their concomitant fate remains unknown. Similar heterogeneity with EVs isolated using a 
similar protocol to ours, has been reported earlier in a study by Kanada et al. (2015) (Kanada et al., 
2015). In this study, MVs were described as significantly more effective carriers of siRNA, mRNA 
and DNA that were transiently expressed in the EV producing cells, partially because they carried 
more of these molecules than the corresponding EXOs. The results also suggested that the nucleic 
acid cargo of EVs was primarily degraded in the endo/lysosomal compartment, leading to no gene 
silencing or expression except for plasmid DNA delivery. Since functional EV-mediated delivery of 
mRNA and other RNA species has been reported elsewhere (Alvarez-Erviti et al., 2011, Ohno et al., 
2013, O'Brien et al., 2015), the negative results in the study by Kanada et al. may be due to cell 
line-specific differences in the EV internalization mechanisms. Certain EVs have been shown to be 
dependent on caveolar endocytosis, which is an endocytic pathway that does not necessarily lead 
to degradation by fusion with lysosomes, the classical end point in other pathways (Kiss, Botos, 
2009). EVs from Epstein-Barr virus-infected cells for example have been shown to be dependent 
on caveolin-mediated cellular uptake (Nanbo et al., 2013). Targeting caveolar endocytosis might 
therefore be a viable strategy for improving EV-mediated functional transfer of biomolecules, 
avoiding their degradation. Caveolae and clathrin-mediated endocytosis as well as 
micropinocytosis have also been reported to mediate transcytosis, where cargo passes through 
the internalizing cell (Elkin, Lakoduk & Schmid, 2016, Matsumoto et al., 2017). Transcytosis has 
been suggested as a possible mechanism for EVs to cross biological barriers, such as the blood-
brain-barrier, which normally inhibits the crossing of large particles and hydrophilic drugs to the 
brain (Matsumoto et al., 2017). Therefore, targeting transcytosis could be a beneficial strategy for 
EV-mediated drug delivery to the brain and other restricted tissues.  
In study (III), no separation of EV subpopulations was performed by differential 
centrifugation, so similar comparison between 20K MVs and 110K EXOs is not available. However, 
density-related differences were observed in the IEVs, with heavier IEVs containing more protein 
and viral DNA per particle. The amount of viral DNA was also reflected in the functionality of IEVs, 
in that the lightest IEVs displayed reduced cytotoxicity, when compared to the heavier IEV 
fractions. Therefore, this reduced cytotoxicity can be explained by an insufficient amount of viral 
DNA for infection. Nuclear import of naked, exogenous DNA in cells is not very efficient due to its 
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degradation and slow migration through the nuclear pore complex (NPC) (Dean, Strong & Zimmer, 
2005, Lechardeur et al., 1999, Salman et al., 2001, Bai et al., 2017), which would imply that a 
considerable amount of DNA needs to be endocytosed in order for it to be imported into the 
nucleus. Because cells can be saturated by EVs as was observed in study (I) and by others 
(Heusermann et al., 2016) and therefore their rate of uptake is limited, the concentration of cargo 
per vesicle can determine if the cargo’s function will be fulfilled. As a simplified case of degradable 
biomolecular cargo such as DNA in cells for example, a critical concentration in the cell required 
for effective nuclear delivery cannot be reached via EV-mediated delivery if the rate of DNA intake 
is not greater than the rate of DNA degradation prior to nuclear transport. Therefore, due to this 
and the saturation effect, EVs with too small DNA per vesicle content could not cause an effective 
transfection of the recipient cell, which was observed regarding fraction 1 IEVs in study (III), even 
though they did contain viral DNA as well, and in theory the nuclear uptake of only one copy could 
lead to a successful infection. In contrast to EVs, the mechanism of virion-mediated adenoviral 
DNA import protects the DNA during intracellular transport. The viral DNA is carried to the NPC 
still packed in the viral capsid, from where it is then directed into the nucleus through the NPC, 
and therefore remains shielded from the DNA degrading cytoplasmic nucleases (Fay, Panté, 2015). 
For this reason, EV-mediated viral DNA delivery can be less effective if it is based on releasing the 
DNA content unprotected into the cytoplasm. However, this mechanism remains unknown at this 
point and it may also vary between different EV types and DNA sequences. For example, some 
DNA sequences act as guides for nuclear transport that improve transfection efficiency (Sebestyen 
et al., 1998) and in theory could be enriched in EVs for a more effective nuclear delivery.  
 
5.3 Extracellular vesicles act as alternative carriers of oncolytic adenovirus 
genome to non-enveloped virions 
EVs are more flexible as therapeutic delivery agents for viral DNA regarding the initial cell 
recognition and cellular uptake, for which virions depend on the presence of a specific receptor on 
the cell surface. For this reason, IEVs are able to infect cells that are lacking the receptors required 
by a free virion (Ran et al., 2016). Some IEVs have also been shown to be resistant to opsonization 
by antiviral antibodies and overall innate antiviral immune response that is triggered by the 
recognition of virions by the immune cells (Ran et al., 2016, Maguire et al., 2012). This was not the 
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case in study (III), as the IEVs were completely neutralized by adenovirus recognizing antibody, 
which means that they would most likely also induce a similar immune response as free virions. 
The results also indicated that an entire capsid is not present inside the IEVs, but instead the 
vesicles are coated with viral proteins and DNA, which are able to mediate the infection like a 
whole virion would. Optimally, from a therapeutic perspective, if an entire adenovirus were 
encapsulated inside an EV, it should retain the efficient intracellular DNA transport mechanism 
that is characteristic to the virus, while also attaining the cellular targeting and immune evasion 
properties of EVs. Encapsulation of virions would naturally be restricted to EVs that are larger than 
the virion (>100 nm in diameter in the case of adenoviruses), but any size dependence should not 
apply to the IEVs described in study (III), though it was not specifically evaluated. It should also be 
noted, that the IEVs are a naturally occurring phenomenon and not something artificially induced 
such as PTX-EVs in study (I). The enrichment of hexon protein to IEVs especially might indicate that 
the formation of IEVs is intentional for the spreading of the virus, since hexon is the protein 
responsible for transporting the viral DNA into the nucleus and probably the most important one 
in this regard to be included in the IEVs (Smith et al., 2008). Therefore, any medical trials studying 
oncolytic viruses for cancer treatment also induce the production of IEVs in the treated cancer 
cells and they are already partially involved in the observed therapeutic outcomes. Given that 
clinical trials involving oncolytic viruses rarely show complete tumor eradication, naturally 
occurring IEVs are likely not effective enough to kill all cancer cells in the patients. While the exact 
contribution of IEVs is difficult to predict, future studies regarding oncolytic virotherapy should 
also start focusing on them, by for example optimizing the virus by genetic engineering to increase 
the loading efficiency of its genome into IEVs by using guiding sequences that target nucleic acids 
to EVs, inducing the incorporation of useful proteins for improved cell targeting and immune 
response against cancer. These efforts of virus engineering could also be combined with 
engineering IEVs for optimal intravenous administration by improving their lifetime in circulation 
and cancer targeting.  
Cancer immunotherapy is another promising approach for treating cancer, where 
cancer cells are only the indirect target of the treatment, as the primary focus is the antigen 
presenting cells that are activated against cancer cells. IEVs could also be useful in this approach, 
given that they also possess direct anti-cancer activity, as compared to plain cancer-derived EVs 
that have been assessed for cancer immunotherapy applications. The underlying mechanisms of 
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successful oncolytic virotherapy have been suggested to involve activation of an anti-tumor 
immune response by the presence of the virus in the tumor, besides the direct killing of infected 
cancer cells (Lawler et al., 2017). In this regard, IEVs carrying both viral and cancer-derived 
antigens could prove as a powerful anti-cancer vaccine, where the generation of an immune 
response against cancer antigens could be boosted by the presence of viral antigens that contain 
pathogen associated molecular patterns readily recognized by immune cells. A similar approach 
has been proposed with oncolytic viruses carrying peptides derived from cancer cells, which has 
shown promising results in generating a stronger anti-cancer immune response (Capasso et al., 
2015). 
While it was not in the main scope of this thesis, it cannot be disregarded that 
besides the therapeutic opportunities of IEVs, they also represent a novel paradigm in virology as 
alternative vectors for viral genome. As virions are defined as protein- or lipid enveloped particles 
containing viral genome with the ability to transmit infection, adenovirus-derived IEVs described in 
study (III) also fit this definition as an enveloped virion, even though adenovirus is a non-
enveloped virus. This is especially contradictory if IEVs do not even contain the adenoviral capsid 
and the IEV-associated DNA seemed to be mostly susceptible to enzymatic cleavage, suggesting 
that it was located on the outside of IEVs, therefore functioning with a different mechanism to 
achieve viral infection in the recipient cells. Adenoviral “naked” virions and IEVs would both 
represent virions of the same species with completely different structures and functionality, 
different sides of the same coin so to say. The classical virion is much more stable and therefore 
more useful in transmitting infection from host to host, while IEVs may be useful in overcoming 
restrictions regarding cell heterogeneity and immune response of the host. In this case, 
adenovirus could be described as a virus that is able to produce both non-enveloped and 
enveloped virions. Future studies regarding the enveloped virions of classically non-enveloped 
viruses can provide important new knowledge about how viral infections spread and how to 





5.4 Biocompatibility, dosing and purity of extracellular vesicles needs 
further clarification 
Naturally, the autologous origin of EVs would also entail that EVs taken from a healthy individual 
would be tolerated completely without side-effects, when returned to the body as a form of 
therapy. In other words, autologous EVs should have optimal biocompatibility in patients, with the 
exception of EVs derived from cancer cells, infected cells or other EVs that promote the spreading 
of diseases. Optimal biocompatibility could be a major advantage in the case of chronic diseases 
that require long-term treatment compared to some synthetic drug carriers, against which the 
patient may develop sensitivity and whose components may accumulate in the liver and cause 
toxic effects (Cho et al., 2009). Also, autologous EVs should be recognized as “self” by the immune 
system, leading to no adverse immune responses, which can occur for example with viral vectors 
(Lawler et al., 2017). While the clearance of EVs by the mononuclear phagocyte system remains an 
issue, if EVs are indeed found to be well tolerated, one might also consider it to be feasible to 
simply saturate the circulation to circumvent the issue of rapid clearance, if their cargo is equally 
harmless in bystander cells. This would at the same time override any need for specific targeting 
by relying on a sufficient number of EVs reaching the target cells passively. This approach could 
provide an advantage in cases where specific targeting is difficult, such as cancer cells. High doses 
of EVs are still impractical due to their costly and laborious large-scale production and purification. 
Given that EVs are non-living biological entities, their maximal applicable dosage should be 
relatively high, but this remains to be firmly established. However, in a study by Smyth et al. 
(Smyth et al., 2015) it was found that injecting mice with 400 μg of EVs as measured by their 
protein mass, caused asphyxiation due to EV aggregation in the lungs. As this phenomenon 
appears to be the only harmful side-effect of EVs reported so far, the accumulation of EVs in the 
lungs could become a considerable indicator for negative effects in future studies regarding the 
question of EV dosage.  
The use of autologous EVs becomes more complicated, when considering EVs from 
patients with certain diseases, as EVs may also mediate the harmful effects of diseased cells. It 
may also be too impractical to collect or cultivate donor cells for the production of sufficient EV 
doses. An alternative option would be to use EVs from healthy donors, such as blood donors or 
EVs produced in cell lines. The immunological compatibility of EVs from non-autologous human 
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sources has not yet been systemically evaluated. Studies have been performed so far with for 
example mesenchymal stem cell-derived EVs for the treatment of a patient with graft-versus-host 
disease (Kordelas et al., 2014). Based on the results, non-autologous human EVs appear to be safe 
to use even with patients in such critical condition. However, it should be noted that recipients of 
donated organs are under immunosuppressive medication, which makes it impossible to draw 
firm conclusions regarding the true immunological compatibility of EVs. Clinical trials have also 
been performed with EVs for the treatment of cancer, using dendritic cell- or ascites-derived EVs 
for lung cancer (Morse et al., 2005), melanoma and colorectal cancer (Escudier et al., 2005, Dai et 
al., 2008) immunotherapy. These studies have also reported good tolerance of the treatment and 
induction of antitumor immunity that increased the survival time of some patients.  
 Another important factor regarding the preparation of clinically relevant EVs is that 
currently there are no methods for establishing their level of absolute purity. It’s a very 
challenging task to determine any universally applicable parameters for EV purity, since the EVs 
are seemingly all different in composition. Generally, EV purity has been evaluated by such 
methods as immunoblotting of EV-associated proteins to evaluate their enrichment, calculating 
protein-to-particle-ratios using total particle- and protein assays (Webber, Clayton, 2013, Nordin 
et al., 2015) and size exclusion chromatography (Nordin et al., 2015, Huang et al., 2015) or field 
flow fractioning (Sitar et al., 2015) to evaluate the presence of small, non-EV-associated proteins. 
Recently there have also been reports of using colorimetric (Osteikoetxea et al., 2015) and optical 
methods such as Fourier-transform infrared spectroscopy (Mihaly et al., 2017) and Raman 
spectroscopy (Gualerzi et al., 2019) that can be useful in determining protein to lipid ratios in EV 
preparations that may be used to represent the purity of EVs. While these methods cannot be 
used to assess absolute values for purity, they could be used in quality control to estimate 
reproducibility between preparations. Each method has its limits, as immunoblotting may be 
sensitive to protein isotypes and the specificity and enrichment of different EV markers vary 
according to the source of EVs, total particle concentrations are difficult to measure reliably 
(Vestad et al., 2017), methods relying on separation by size are sensitive to large contaminants 
and optical methods are affected by non-specific interference from certain contaminating 
molecules. A combination of these methods will be likely to help overcome their individual 
limitations and help determine the purity of EV preparations from different angles. In studies (II 
and III), density gradient centrifugation was used to purify EVs, which is currently considered one 
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of the best methods for EV purification, whereas in study (I), only differential centrifugation was 
used. Most likely the preparations in study (I) did contain contaminating proteins as well as EVs, 
but the results from fluorescence microscopy were comparable to study (II) and the protein per 
particle-ratios in both studies had the same trend of 20K MVs having less protein per particle than 
110K EXOs, though the exact values are not comparable due to changes in the NTA setup used 
between those two studies. The protein per particle values between studies (II) and (III) were also 
very similar, although the values were higher in the high density fractions 5 and 6 in study (III). In 
study (I), trypsinized PTX-EV samples, where any contaminating proteins would have been cleaved 
by the enzyme, were also examined with little observed effect on the cytotoxicity, compared to 
non-trypsinized, where contaminating proteins were left intact. Taken together, these results 
suggest that contaminating proteins did not affect the results regarding PTX delivery in study (I) in 
a significant manner. The presence of contaminants effects general EV characterization the most, 
such as western blotting, size distribution and protein per particle analyses, but the magnitude of 
the effect remains unclear in study (I) regarding those characteristics, as the results were still 




EVs provide a versatile platform for drug delivery, with capacity for carrying both small molecule 
drugs and biological therapeutics as large as the adenoviral genome, though many issues remain 
unanswered regarding their functions and relevance in physiological processes. The production 
and purification of EVs is laborious and their heterogeneity and innate cargo pose a complex 
problem regarding choosing the correct sources and methods for production and purification. 
Additionally, understanding and predicting the behavior and cargo delivery of EVs in the target 
cells is still in its infancy. Regardless of these issues, in studies (I – III) and by others, EVs have been 
proven to work as targeting carriers of versatile therapeutic cargo, which is in part reflected in the 
increasing founding and funding of new businesses focused on developing EVs for diagnostic and 
therapeutic applications. As they resemble naturally occurring liposomes and possess theoretically 
optimal biocompatibility, while at the same time being non-living, EVs represent a model for the 
future of drug delivery research. In this thesis, two simple approaches were examined for 
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preparation of EVs for cancer therapy. The loading of EVs depends on the properties of the 
therapeutic cargo, but in the studies presented (I – III), loading could be achieved relatively easily 
by incubating EVs post isolation with hydrophobic PTX, or during EV biogenesis by infecting the 
secreting cancer cells with the desired oncolytic virus. Both types of therapeutic cargo were 
successfully delivered into autologous cancer cells with retained or even improved cytotoxicity as 
was shown with PTX. EVs were primarily internalized by endocytosis, which changed the 
intracellular distribution of PTX as observed by FLIM for the first time. Additionally, while IEVs 
were shown to be functioning carriers of oncolytic adenovirus DNA, they are also a novel pathway 
of spreading viral infection in general. Indeed, as the complex biology behind different kinds of EVs 
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